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ABSTRACT

The maintenance of normal cell function and tissue homeostasis is dependent on
the precise regulation of multiple signaling pathways that control cellular decisions to
either proliferate, differentiate, arrest cell growth, or initiate programmed cell death
(apoptosis). Cancer arises when clones of mutated cells escape this balance and
proliferate inappropriately without compensatory apoptosis. Deregulated cell growth
occurs as a result of perturbed signal transduction that modulates or alters cellular
behavior or function to keep the critical balance between the rate of cell-cycle
progression (cell division) and cell growth (cell mass) on one hand, and programmed cell
death (apoptosis, autophagy) on the other.
AGC kinases are activated downstream of a wide range of extracellular stimuli by
distinct mechanisms. AGC kinase members such as Aurora-A and Akt regulate
fundamental cellular functions including cell cycle, cell growth and survival.
Inappropriate activation of those kinases has been associated with the development of
diseases such as diabetes, autoimmunity, and cancer. The molecular mechanism of AGC
kinases including Aurora-A and Akt involved in human cancers indicates that Aurora-A
and Akt are important targets for cancer therapeutic strategies.
We demonstrate, for the first time, that Aurora-A interacts with AR and
phosphorylates AR at Thr282 and Ser293 in vitro and in vivo. Aurora-A induces AR
transactivation activity in a phosphorylation-dependent manner.
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Ectopic expression

Aurora-A in LNCaP cells induces the PSA expression and cell survival whereas
knockdown of Aurora-A sensitizes LNCaP-RF cells to apoptosis and cell growth arrest.
These data indicate that AR is a substrate of Aurora-A and that elevated Aurora-A could
contribute to androgen-independent cell growth by phosphorylation and activation of AR.
The NACHT leucine-rich repeat protein 1 (NALP1) is a member of the Ced-4 family and
locates at chromosome 17p13.2 near TP53 locus.

Here we demonstrated frequent

somatic mutations and epigenetic silence of the NALP1 in human non-small cell lung,
breast, ovarian and colon cancer. Restoration of NALP1 resulted in the inhibition of
tumorigenic activity of the cell lines with NALP1 alterations. In addition to apoptosis,
the cells expressing NALP1 largely undergo autophagy. Expression of NALP1 induces
PI3KC3 kinase activity through directly interacts with Beclin 1, a protein required for
activation of PI3KC3.

Moreover, Akt phosphorylates NALP1 and disrupts the

interaction between NALP1 and Beclin 1, leading to abrogation of NALP1-induced
PI3KC3 activation and autophagy.

Taken collectively, these data indicate that the

NALP1 is a novel tumor suppressor gene on chromosome 17p13 and plays an important
role in tumorigenesis by regulation of Beclin 1/PI3KC3 autophagic pathway and that Akt
inhibits autophagy through regulation of NALP1/Beclin/ PI3KC3 cascade.

viii

CHAPTER I

INTRODUCTION

AGC kinase
Protein kinases are key regulatory enzymes that change the properties of a
substrate by attaching a phosphate group to Ser, Thr or Tyr residues (1). The term AGC
kinase was coined by Steven Hanks and Tony Hunter in 1995 to define the subgroup of
Ser/Thr protein kinases that, based on sequence alignments of their catalytic kinase
domain, were most related to protein kinase A (PKA), protein kinase G (PKG) and
protein kinase C (PKC) (2). It is now appreciated that the AGC family contains 60 of the
518 human protein kinases, which have been highly conserved throughout eukaryotic
evolution (3).
For many AGC kinases, activation involves phosphorylation of two highly
conserved regulatory motifs. These are the activation segment (also known as the T- or
activation loop), which is located in the catalytic domain, and the hydrophobic motif,
which is found in a non-catalytic region following the kinase domain. This hydrophobic
motif (HM; Phe-Xaa-Xaa-Phe-Ser/Thr-Tyr) is conserved in most other AGC kinases (Fig
1) (4,5). Although Aurora kinases lacks a C-terminal HM sequence, the inactive structure
of Aurora-A revealed an unoccupied HMpocket. And phylogenetically, Aurora-A kinase
is on the same branch of the kinome tree as AGC kinases. Several AGC kinases also
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contain another important phosphorylation site that promotes their integrity, which is
termed the turn motif. Clearly, as AGC kinases control very important cellular processes
it is inevitable that their dysregulation has serious consequences. The best characterized
pathological state in which AGC kinases are involved is cancer.
Fig 1. AGC kinases. AGC
kinases are listed according to
the properties of their HM
sequence. For kinases with
names in bold, structures have
been determined by X-ray. The
HM sequence is shown in singleletter
amino
acid
code;
hydrophobic residues occupying
the HM pocket are in bold
and phosphorylated residues are
in red

Aurora kinase
Aurora kinases represent a novel family of AGC kinase crucial for cell cycle
control. The first Aurora kinase was discovered in Drosophila (6). Because its mutations
resulted in a failure of centrosome separation, leading to the formation of monopolar
spindles, it was given the name ‘‘Aurora,’’ reminiscent of the North Pole. Since then,
homologues of Aurora have been identified in different species. Saccharomyces
cerevisiae has a single Aurora kinase: Ipl1 (increases in ploidy 1). In Caenorhabditis
elegans, Drosophila, and Xenopus, there are two types of Aurora kinases: Aurora-A and
Aurora-B. Mammals own at least three Aurora kinases: Aurora- A, Aurora-B, and
Aurora-C (for nomenclature). Special interest in Aurora kinases has arisen since people
2

discovered that defects in these kinases lead to severe mitotic abnormality. Silencing of
Aurora-A leads to abnormal spindle morphology in C. elegans, Drosophila, and human
cells (7, 8, 9), whereas disruption of Aurora-B causes chromosome misalignment and
cytokinesis failure in both Drosophila and HeLa cells (10, 11), indicating their multiple
roles in centrosome function, chromatid separation, and cytokinesis. Aurora kinases are
overexpressed in a variety of tumor cell lines (12, 13, 14), suggesting that these kinases
might play a role in tumorigenesis. In particular, Aurora-A can transform certain cell
lines when overexpressed (15, 16). Inhibitors of Aurora kinases are used in cultured cells
and xenograft models to treat cancer, and an encouraging effect has been shown (17, 18).
Phosphatidylinositol 3-kinases
The phosphatidylinositol 3-kinases (PI3Ks) are members of a unique and
conserved family of intracellular lipid kinases that phosphorylate the 3′-hydroxyl group
of phosphatidylinositol and phosphoinositides. This reaction leads to the activation of
many intracellular signaling pathways that regulate functions as diverse as cell
metabolism, survival and polarity, and vesicle trafficking. A host of intracellular
signaling proteins have evolved the ability to bind to the lipid products of PI3Ks and
therefore become activated by PI3K signaling. The most ancient role for this family of
enzymes is probably to mark specific cellular membranes for trafficking events, and this
seems to be the primary function of the single form of PI3K that is found in yeast: Vps34
(vacuolar protein-sorting defective 34). However, in multicellular eukaryotes, additional
isoforms of PI3K have evolved for the dedicated purpose of signal transduction. Genetic
experiments in Caenorhabditis elegans, Drosophila melanogaster and mice clearly
implicate PI3K as a key component in insulin and growth factor responses that regulate
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metabolism and cell growth. Over the past decade, it has become evident that the PI3K
signaling pathway is one of the most highly mutated systems in human cancers,
underscoring its central role in human carcinogenesis. PI3K classification and signal
transduction PI3Ks are grouped into three classes (I–III) according to their substrate
preference and sequence homology (Fig. 3). Different classes of PI3K have distinct roles
in cellular signal transduction, as do the different isoforms that can exist within each class
(25, 26, 27).
Class I PI3Ks. Class I PI3Ks are divided into two subfamilies, depending on the
receptors to which they couple. Class IA PI3Ks are activated by growth factor receptor
tyrosine kinases (RTKs), whereas class IB PI3Ks are activated by G-protein-coupled
receptors. Class IA PI3Ks are heterodimers of a p85 regulatory subunit and a p110
catalytic subunit. In mammals, there are numerous isoforms of each subunit.
Interestingly, the p110β isoform of class IA PI3K is regulated not only by the p85
regulatory subunit but also by binding to Gβγ subunits of heterotrimeric G proteins.
Therefore, the class IA p110β isoform might integrate signals from GPCRs as well as
RTKs. Class IB PI3Ks do not have p85 family regulatory subunits and therefore are not
regulated by RTKs. They seem to be exclusively activated by GPCRs through interacting
directly with the Gβγ subunit of trimeric G proteins3. Similar to class IA PI3Ks, class IB
PI3Ks are heterodimers of regulatory and catalytic subunits. The p101 regulatory subunit
facilitates the activation of the p101–p110γ heterodimer by Gβγ4. Class I PI3Ks are
involved in many important physiological processes. By acting downstream of an insulinlike hormone, the class IA PI3K in C. elegans regulates dauer formation, metabolism and
longevity. The class IA PI3K in D. melanogaster is part of a similar pathway that
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controls cell growth and proliferation. In mammals, class I PI3Ks regulates glucose
homeostasis, cell migration, growth and proliferation (28).
A

B

S/T Kinase domain

Heat

Heat

WD40

WD40

WD40

WD40

WD40

PIK3R4 (p150)

Fig. 2. Classification of phosphatidylinositol 3-kinase (PI3K) family members. There are three classes
(I–III) of PI3K, which show distinct substrate preferences in vitro (A), The domain structures of various
PI3K isoforms are shown in panel (B). Class IA PI3K is a heterodimer that consists of a p85 regulatory
subunit and a p110 catalytic subunit. Class IB PI3K is a heterodimer consisting of a p101 regulatory
subunit and a p110γ catalytic subunit. Class II PI3K consists of only a p110-like catalytic subunit. Class III
PI3K consists of Vps34 (vacuolar protein-sorting defective 34) and a regulatory subunit p150.

Class II PI3Ks. Class II PI3Ks consist of only a single p110-like catalytic
subunit2. In vitro, these enzymes preferentially phosphorylate phosphatidylinositol and,
to

a

lesser

extent,

phosphatidylinositol-4-phosphate

(PI-4-P).

However,

phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) is a poor substrate for these
enzymes.Class II PI3Ks bind clathrin and localize to coated pits, indicating a function in
regulating membrane trafficking and receptor internalization. In addition, class II PI3Ks
can be activated by RTKs, cytokine receptors and integrins. Their specific functions in
response to these activators, however, are not well understood (29).
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Class III PI3Ks. The yeast class III PI3K, Vps34, was originally identified in
budding yeast as the gene product required for trafficking vesicles from the Golgi
apparatus to the vacuole. Vps34 has been implicated in autophagy, which is a cellular
response to nutrient starvation. Relatively little is known about the specific functions of
class II and III PI3Ks. Furthermore, the commonly used PI3K inhibitors, wortmannin and
LY294002, inhibit class I and class III PI3Ks, and to a lesser extent class II PI3Ks, as
well as other PI3K-like protein kinases (30,31).
VPS34: the sole class III PI3K. Vps34 is conserved from lower eukaryotes to
plants and mammals (in which it is also known as PIK3C3), and is an endosomal kinase
that can acquire multiple functions through association with distinct multiprotein
complexes. Vps34 forms a constitutive heterodimer with Vps15, which is myristoylated,
tethering the Vps15–Vps34 complex to intracellular membranes.Vps34 is found in
distinct multiprotein complexes, which define its biological roles. In yeast, three
complexes have been reported (FIG. 3a). In mammals, VPS34 complexes are more
elaborate and not well defined, with identification of new components ongoing (FIG. 3b).
Unlike in yeast, some mammalian VPS34 partners are not exclusively limited to one
specific function. Some proteins in the Vps34 complexes are conserved in evolution and
a basic configuration based on what is known in yeast can be identified in mammals.
These complexes contain beclin 1, ATG14l (also known as barkor) and ultraviolet
radiation resistance associated gene protein (UVRAG), the mammalian homologues of
yeast Vps30, Atg14 and Vps38, respectively. Vps34 associated proteins also regulate,
directly or indirectly, the catalytic activity of Vps34. For instance, it has been shown that
Bax interacting factor 1 (BIF1) stimulates mammalian VPS34 kinase activity in the
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UVRAG–beclin 1 complex.

Vps34 has a lipid substrate specificity limited to PtdIns,

generating PtdIns3P (FIG. 2a). Kinase dead Vps34 cannot rescue the phenotype of Vps34
deletion in yeast or C. elegans, indicating that the lipid kinase activity of Vps34 is
essential for its biological function.

Figure 3 Vps34–Vps15 complexes in yeast and mammals. a | In yeast, vacuolar protein sorting 34
(Vps34)–Vps15–Vps30 is bound to either autophagy-related protein 14 (Atg14) (in complex I) or to Vps38
(in complex II). In a third complex (which we refer to as complex III), Vps34–Vps15 binds guanine
nucleotide-binding protein 1α (Gpa1), the yeast homologue of the mammalian Gα subunit of heterotrimeric
G proteins, in a GTP-dependent manner. This complex localizes at endosomes and is required for
pheromone signalling to mitogen-activated protein kinases in yeast. b | Mammalian VPS34 (also known as
PIK3C3) complexes contain beclin 1, ATG14L (also known as barkor) and ultraviolet radiation resistanceassociated gene protein (UVRAG), the homologues of yeast Vps30, Atg14 and Vps38, respectively. In
mammals, the VPS34 complexes are more elaborate, with additional components that are not present in
yeast Vps34 complexes. These include Bax-interacting factor 1 (BIF1), activating molecule in BECN1regulated autophagy protein 1 (AMBRA1), rubicon and ATG14L, which are present in the beclin 1–VPS34
autophagic complex. The phosphatidylinositol (PtdIns)-3 phosphatase myotubularin 1 (MTM1) is present
in other, poorly defined VPS34 complexes.

Vps34 and autophagy. Vps34 was first shown to be required for autophagy in
yeast. In D. melanogaster, the role of VPS34 in autophagy is largely limited to the early
steps of autophagosome formation and a kinase defective VPS34 mutant phenocopies the
effect of VPS34 deletion, underscoring the role of VPS34 kinase activity and thus
PtdIns3P generation in autophagy. The role of VPS34 in autophagy in mammals is not
well defined. The source of the autophagosome is still under debate and has been linked
7

to the Golgi, plasma membrane and endoplasmic reticulum (ER). Recent data indicate
that PtdIns3P enriched structures (called omegasomes based on their cup shape) seem to
form from ER membranes on amino acid starvation of mammalian cells, indicating that
VPS34 could be recruited to the ER to form the autophagosome in response to starvation
(32, 33, 34).
Autophagy
Autophagy is a lysosomal pathway used by eukaryotes for degrading and
recycling various cellular constituents, such as long-lived proteins and entire organelles.
There are three main forms of autophagy: microautophagy, macroautophagy, and
chaperone-mediated autophagy. Microautophagy and the mammalian-specific chaperonemediated autophagy directly involve the lysosome, which either engulfs small portions of
cytosol or receives chaperone-associated cargoes, respectively. Macroautophagy is
responsible for the turnover of organelles and portions of cytosol sequestered in a doublemembrane-bound vesicle, the autophagosome.

Autophagosomes originate from a

precursor structure, the phagophore, which starts growing at both ends and finally closes
and wraps the bulk cytoplasm and organelles (FIG. 4). Autophagosomes slide along
cytoskeletal structures and fuse with lysosomes, forming a single large and membranesurrounded vesicle called the autophagolysosome, where both their membrane and
contents are degraded by lytic enzymes. Most of the genes involved in macroautophagy
(hereafter autophagy), the so-called Autophagy-related (Atg) genes, have been
discovered in S. cerevisiae. These include genes that regulate autophagosome formation,
which requires two evolutionarily conserved ubiquitin-like conjugation systems—the
Atg12-Atg5 and the Atg8 (LC3)-PE (phosphatidylethanolamine) systems (FIG. 4)—as
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well as genes that function in other stages of autophagy. Atg genes were originally
described in yeast, and in some cases their orthologs have been isolated and functionally

Fig. 4 Autophagosome Formation in Vertebrates. (A) Autophagosomes (AF) originate from a
precursor structure (phagophore), which grows, closes, and wraps the cytoplasmic components and
organelles. Eventually, the autophagosome fuses with the lysosome (Ly), forming a structure termed
autophagolysosome or autolysosome (AL). The contents of the autophagosome are then degraded by the
lysosomal enzymes.
(B) Autophagosome nucleation is driven by phosphatidylinositol (PI)
phosphorylation. This process (highlighted in blue) is mediated by a lipid kinase signaling complex (Beclin
1, Vps15, Vps34). Ambra1 promotes Beclin 1/Vps34 interaction, whereas Ulk1 is downstream of mTOR
(which is inhibitory for autophagy) and is involved in autophagy induction (see text), although it is not a
subunit of the Beclin 1/Vps34 complex. UVRAG and Bif-1 have been described as additional regulators of
the Beclin 1/Vps34 complex. (C) Autophagosome elongation is triggered by lipid modification of LC3 (by
phosphatidylethanolamine, PE), as highlighted in yellow. This process is mediated, among others, by Atg7
(an E1-like ubiquitin conjugating enzyme), Atg3 (an E2-like ubiquitin conjugating enzyme), and Atg4C, to
which LC3 is bound at first. Atg7 also acts in an ubiquitin-like conjugation system involving the E2-like
ubiquitin conjugating enzyme Atg10 and Atg12/Atg5 which, at the end of the process, are transferred to
Atg16L. The complex Atg12/Atg5/Atg16L mediates LC3-PE binding to the autophagosome membranes.

characterized in mammals. A core molecule in autophagy regulation is the kinase
mammalian Target of Rapamycin (mTOR). By sensing signals that monitor nutrient
levels, mTOR can trigger protein translation by specific phosphorylation of the ribosomal
protein S6 kinase (pS6K). When nutrients are lacking, mTOR repression shifts cellular
metabolism toward autophagy and recycling of cytosolic constituents (FIG. 4), although
the precise targets of mTOR in autophagy remain unidentified.
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The discovery of the

molecular basis of autophagy has enabled the search for links with human pathological
conditions. Genetic or pharmacological alteration in this process impairs cell survival rate
or cell metabolism, thereby affecting tissue homeostasis. Many neurodegenerative
conditions, for example, can be traced back to defective autophagy. The role of
autophagy in Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, or
Alzheimer’s disease may reside in the failure to clear aggregates of mutated toxic
proteins (35).

Autophagy has also been identified as a crucial process in oncogenesis

and cancer progression. Several autophagy-related proteins have tumor suppressor
activity (Beclin 1, Atg5, Bif-1, Atg4C, UVRAG), and some autophagy gene mutations,
detected in humans or induced in cellular or animal models, can lead to an accumulation
of DNA damage and genome instability (36). In cancer progression, autophagy may, on
the other hand, provide tumor cells with a survival strategy, thus suggesting a therapeutic
use for autophagy downregulation in solid tumors (37, 38). Further, antigen presentation,
innate immune signaling, and pathogen degradation may all involve autophagosome
recruitment and activity, and autophagy plays an important role in immunity and
infectious diseases.
Autophagy and Cancer
Cancer is one of the first diseases genetically linked to autophagy malfunction.
The ATG gene beclin 1 is monoallelically deleted in 40–75% of cases of human breast,
ovarian, and prostate cancer. This is probably mechanistically important in
tumorigenesis, because mice with heterozygous disruption of beclin 1 have decreased
autophagy and are more prone to the development of spontaneous tumours including
lymphomas, lung carcinomas, hepatocellular carcinomas, and mammary precancerous
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lesions. Further, immortalized kidney and mammary epithelial cells derived from beclin 1
heterozygous-deficient mice are more tumorigenic when transplanted in vivo. Other
components that enhance the autophagic activity of the Beclin 1/class III
phosphatidylinositol 3-kinase (PI3K) complex, including ultraviolet irradiation
resistance-associated gene (UVRAG), Ambra1 and Bif-1 may also play a role in cell
growth control and/or tumour suppression. In animal models, additional ATG genes
including atg4c also exert tumour suppressor effects, suggesting that tumour suppression
may be a shared property of autophagy proteins that act at different steps of the pathway
(Fig. 4). Beyond a role for ATG genes in tumour suppression, there is accumulating
evidence that autophagy signalling regulation is tightly linked to oncogenic signalling.
Several commonly activated oncogenes (for example, those encoding class I PI3K, PKB,
TOR, Bcl-2) inhibit autophagy, whereas commonly mutated or epigenetically silenced
tumour suppressor genes (such as those encoding p53, PTEN, DAPk, TSC1/TSC2)
stimulate autophagy.
These genetic links between defects in autophagy regulation or execution and
cancer suggest that autophagy is a true tumour suppressor pathway. However, the
mechanisms by which it functions in tumour suppression remain largely undetermined.
Autophagy may directly regulate cell growth, functioning as a brake to prevent cells from
inappropriately dividing in the absence of appropriate trophic support (even though it
may promote cell survival in this setting). The increased frequency of mitochondrial
DNAmutations in autophagy-deficient yeast suggests that mitochondrial turnover
mediated by basal autophagy may prevent genotoxic stress and DNA damage. Indeed,
recent studies strikingly reveal that both beclin 1 and atg5 function as ‘guardians’ of the
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cellular genome. Immortalized epithelial cells with mono-allelic or bi-allelic loss of
beclin 1 or atg5, respectively, display increased DNA damage, gene amplification, and
aneuploidy, especially during ischaemic stress, in parallel with increased tumorigenicity.
It is not yet known how autophagy deficiency compromises genomic stability.
A seeming paradox is that autophagy, a pathway that functions primarily in cell
survival, also functions in tumour suppression (Fig. 4), but two hypotheses have recently
been proposed to explain this paradox. First, when tumour cells cannot die by apoptosis
upon exposure to metabolic stress, autophagy may prevent death by necrosis, a process
that might exacerbate local inflammation and thereby increase tumour growth rate.
Second, as noted above, even though autophagy promotes cell survival in the setting of
metabolic stress in the tumour microenvironment, it acts concurrently to prevent genomic
instability. An additional possibility is that despite its pro-survival effects, autophagy
activation during metabolic stress (and high density conditions) prevents cell growth.
Although the pro-survival effects of autophagy may often be counterbalanced by its
tumour suppressor effects, an area of growing interest is the potential contribution of
these pro-survival effects to tumour cell resistance to chemotherapy; recent studies have
shown that genetic or pharmacological inhibition of autophagy enhances cytoxicity of
cancer chemotherapeutic agents. Consequently, clinical trials are in progress (based on
studies in mouse models) to disrupt autophagic degradation to maximize the effects of
cancer cytotoxic agents. Thus, much as in neurodegenerative and cardiac diseases, it may
be necessary to differentially target autophagy in a context-specific and diseasestagespecific manner; autophagy augmentation may be effective in preventing tumour
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formation and progression, whereas autophagy inhibition may be helpful in promoting
tumour regression.
Akt (also named PKB)
Origin and structure of Akt. Recent evidence indicates that the serine/threonine
protein kinase Akt mediates many of the downstream events controlled by PI3K. The
three widely expressed isoforms of Akt (Akt1/PKBα, Akt2/PKBβ and Akt/PKBγ) are
each composed of an N-terminal PtdIns(3,4,5)P3- and PtdIns(3,4)P2-binding PH domain
and a C-terminal kinase catalytic domain. Following the activation of PI 3-kinase
stimulated by diverse stimuli such as hormones, growth factors, and extracellular matrix
components, Akts are recruited from the cytosol to the plasma membrane through their
interaction with PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2 where they are thought to undergo a
conformational change and become activated by phosphorylation at two residues. One
resides in the T-loop (also known as the activation loop) of the kinase domain of Akt, and
the other is located at C-terminal. Akt isoforms are phosphorylated at the T-loop (Thr308
in Akt1Thr309 in Akt2 and Thr302 in Akt3, respectively) by PDK1 and this appears to be
the major input required for the activation of Akt and latter site could be
autophosphorylated or by some unknown protein kinase, like ILK or hypothetical PDK2
(39,40). Akt regulates many cellular processes including metabolism, apoptosis, and
proliferation. Recent evidence indicates that Akt is frequently constitutively active in
many types of human cancer. Constitutive Akt activation can occur due to amplification
of Akt genes or as a result of mutations in components of the signalling pathway that
activates Akt. Although the mechanisms have not yet been fully characterized,
constitutive Akt signalling is believed to promote proliferation and increased cell survival
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and thereby contributes to cancer progression (41). The origins of Akt research can be
traced back to 1977, Staal and co-workers isolated a retrovirus from mink lung epithelial
cells infected with AKT8, and showed that it contained a cell-derived oncogenic
sequence, which they termed akt (42). In 1991, several independent lines of research
converged on the discovery of cDNA encoding Akt (43-44). These cloning works
established Akt/PKB as a novel phospho-protein kinase that was widely expressed, and
paved the way for future experiments into the role of Akt/PKB in diverse cellular
processes. Today, three main isoforms of Akt/PKB have been identified in mammalian
cells: Akt1, Akt2 and Akt3 (Fig. 5). The current explosion of interest in Akt/PKB further
opened up to diverse cellular processes investigation such as glucose metabolism,
transcription, apoptosis, proliferation, migration and angiogenesis.

Fig 5. Structure organization of three
major Akt/PKB isoforms. It is shown in
comparison to virus coding v-Akt and SGK.
All Akt variants contain a PH domain, a
catalytic domain and a putative regulatory
tail at the C-terminus. SGK has a similar
structure but lacks of PH domain. V-Akt is
an in-frame fusion of Akt1 with a portion of
retroviral group-specific antigen (gag).
Amino acid positions are shown for mouse
proteins. Serine and Threonine residues
whose phosphorylation is required to
activation are indicated in open boxes.
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Model of Akt activation

Akt exists in the cytosol of unstimulated cells in a

low-activity conformation. Upon activation of PI3K, PtdIns(3,4,5)P3/PtdIns(3,4)P2 are
synthesized at the plasma membrane and Akt interacts through its PH domain with these
lipids. This induces the translocation of Akt from the cytosol to the inner leaflet of the
plasma membrane and a conformational change which converts Akt into a substrate for
PDK1, perhaps by exposing the Thr308 and Ser473 phosphorylation sites. PDK1 – which
may already be membrane-localized by virtue of its PH domain bound to, for example,
basal levels of PtdIns(3,4)P2/PtdIns(3,4,5)P3 [or PtdIns(4,5)P2] – then phosphorylates and
activates Akt. PDK1 in this location of the cell may also be complexed with a PKCrelated kinase or an equivalent protein, not only enabling it to phosphorylate Akt on both
Thr308

and

Ser473,

but

also

inducing

responsiveness

of

PDK1

to

PtdIns(3,4,5)P3/PtdIns(3,4)P2. As mentioned before, it is still in doubt if that Ser473 is
autophosphorylated or phosphorylated by some PDK2. It has also been demonstrated that
Akt can multimerization through their PH domains when activated and the interaction
among such domains can enhance Akt activity (45, (Fig. 6)). Several reports have
indicated that Akt can be activated in cells by a mechanism independent of PI3K
activation, for example in response to heat shock, or increases in intracellular Ca2+ or
cAMP (46-47). Konishi et al. [48] reported that Akt is activated by heat shock in NIH3T3
fibroblasts and that this response was not inhibited by wortmannin. However, Shaw et al
showed that Akt, activated by heat shock as well as oxidative stress could be completely
suppressed by the PI3K inhibitors wortmannin and LY294002 (49). Agonists which
increase Ca2+ levels in cells have been reported to activate Akt in a PI3K-independent
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manner through the Ca2+/calmodulin-dependent protein kinase kinase (CAMKK) (50).
The stimuli of Akt activation from extensive studies in different fields are summaried in
the table 1.

Table 1. 1. List of stimuli that activate Akt

Downstream targets of Akt. To understand the physiological functions of Akt it
is important to identify its downstream substrates. It was originally established that the
minimum motif in a peptide enabling Akt phosphorylation is Arg-Xaa-Arg-Yaa-ZaaSer/Thr-Hyd (RXRXXS/T), where Xaa is any amino acid, Yaa and Zaa are preferably
small residues other than glycine, and Hyd is a bulky hydrophobic residue (phenylalanine
or leucine) (51). Recently a number of in vivo and in vitro studies have identified
substrates for Akt, including BAD (at Ser 136) (52), glycogen synthase kinase 3 (GSK3)
(530, 6-phosphofructo-2-kinase (54), caspase-9 (55), endothelial nitric-oxide synthase
(56,57), phosphodiesterase 3B (60), rac1 (61), raf-1 protein kinase (62,63), mammalian
target of rapamycin (mTOR) (54), breast cancer susceptibility gene 1 (BRCA1) (65),
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insulin receptor substrate 1 (IRS-1) (66), and forkhead transcription factors (67,68),
cAMP-responsive element binding protein (CREB) (69), human telomerase reverse
transcriptase (hTERT) (70) and MDM2 (71,72). (Most of them are shown in Fig. 6 and
Table. 2).

Figure. 6. Proposed model for Akt/PKB regulation and downstream target of Akt. Activation of AKT
through the PI3K pathway involves recruitment of the PH domain binding to PI3K product, PI(3,4,5)P3, leading to
conformational change of Akt, which results in phosphorylation of Thr308 and Ser473 by PDK1 and mTORC2,
respectively. Upon its release from the membrane, Akt becomes available to phosphorylate: 1) GSK-3β, leading to
its inactivation; 2) pro-apoptotic proteins BAD, and transcription factor Forkhead resulting in reduced binding of
BAD to Bcl-XL and inhibition of caspase-9 protease activity and p27 and Fas ligand transcription; 3) IKKα leading
degradation of IKBα and activiation of NF-κB and 4) E3 ligase, MDM2, induce p53 ubiquitination and degradation.

Physiological functions of Akt. Targets of Akt in promoting cell survival (antiapoptosis function) Overexpression of Akt has an anti-apoptotic effect in many cell types.
In this anti-apoptotic machinery, BAD (Bcl-2/Bcl-XL-antagonist, causing cell death),
Forkhead family proteins, human caspase-9 and IκB kinase α have been reported to be
the downstreams for active Akt.
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BAD can form heterodimer with anti-apoptotic proteins Bcl-2 or Bcl-XL and
therefore, prevent them from exerting their anti-apoptotic function. Akt can
phosphorylate BAD at Ser136 (52), and Akt also induce BAD phosphorylation at Ser112
through PAK1 (p21-activating kinase 1) (73). After phosphorylation at Ser112 and
Ser136, phosphorylated BAD binds to 14-3-3 protein and is subjected to degradation,
even though phosphorylation at Ser 155 has been reported to be important for binding to
14-3-3 (74). A major question still remains here whether Akt can enhance the activity of
anti-apoptotic proteins, like Bcl-2 or Bcl-XL, in phosphorylation-independent manner.
Caspase-9 is a protease crucial in the initiation and possibly later stages of
apoptosis, by forming apoptosomes with Apaf-1 and cytochrome c. Human procaspase9 has been reported to be phosphorylated and inhibited by Akt (55). It is still unclear how
important and/or general this is for Akt-mediated regulation of apoptosis, because the site
which Akt phosphorylates in human caspase-9 is not conserved in the mouse, rat and
monkey homologues (75). Moreover, it has been reported that Akt cannot effectively
block apoptosis once after cytochrome c release (76).
Forkhead protein (FH) is one example of transcription-based mechanisms by
which Akt can interfere with cell death have been reported. Forkhead family contains
three members of transcription factors including FKHR, FKHRL1 and AFX (68,77). A
link between Akt and FH transcription factors was first established in C. elegans, where
the insulin receptor/PI3K/PDK1/AKT pathway suppresses the action of the DAF16 gene
which encodes a transcription factor belonging to the FH family (67). In serum-starved
mammalian cells, FH transcription factors are localized predominantly in the nucleus,
whereas upon cellular stimulation, they transport to the cytosol. This subcellular
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localization change is regulated through phosphorylation by Akt (68). This
phosphorylation promotes the export of FKHR, FKHRL1 and AFX from the nucleus to
the cytosol, where they interact with the 14-3-3 proteins, effectively holding them in the
cytoplasm, away from their target genes (Fas and p27) in the nucleus (68,77,78). It
remains to be investigateded how common this link with Fas signalling is in different cell
systems.
A second transcription-dependent anti-apoptotic action of Akt may operate via the
transcription factor NF-κB (58,59). When bound to its cytosolic inhibitor, IκB, NF-κB is
retained in the cytoplasm. Upon its phosphorylation by IκB kinases (IKKs), IκB is
degraded. This allows NF-κB to transport into the nucleus and activate the transcription
of anti-apoptotic proteins such as inhibitor-of-apoptosis (IAP) proteins c-IAP1 and cIAP2 (79). Akt1 has been reported to interact with and phophorylates IKKα and activate
NF-κB pathway (58, 59). Whether the other IKKs also can be regulated by Akt directly
or in directly, or Akt regulates NF-κB activity via IκB-dependent manner, are still under
investigated. In addition, there are still other transcription factors that can be indirectly
phosphorylated by Akt, including CREB (cAMP-responsive element binding protein) and
E2F (69,80).
Role of Akt in insulin signaling transduction. Nearly all the physiological
responses of a mammalian cell to insulin are prevented by PI3K inhibitors (81), and the
mechanisms through which Akt is involved include phosphorylation of GSK-3, 6Phosphofructose 2-kinase (PFK2), phosphodiesterase-3B (PDE-3B), mTOR and insulin
receptor substrate-1 (IRS-1) (53,54,60,64).
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GSK-3, the first cellular substrate for Akt, initiated the search for other
downstream targets and also opened the way for a bioinformatic approach to find more
and more physiological substrates for Akt. GSK-3 has been shown to be phosphorylated
at Ser 9 and inhibited by active Akt induced by insulin, which promotes glycogen
synthesis (53). 6-Phosphofructose 2-kinase (PFK2), the rate-limiting enzyme in
mammalian glycosis, has been reported to be phosphorylated and activated
predominately by Akt even though it is also phosphorylated by MAPKAP kinase-1 and
p70S6K (54,82). Apart from direct phosphorylation and regulation GSK-3 and PFK-2 in
response to insulin stimulation, Akt has been involved in glucose transport via promoting
GLUT4 (glucose transporter-4) translocation and upregulating GLUT1 expression (83).
The enhancement of protein synthesis is another biological response to insulin
observed in a variety of cell types, but major in skeletal muscle and adipose tissues (83).
A crucial event is the phosphorylation of 4E-binding protein-1 (4E-BP1) and its
dissociation from eukaryotic initiation factor 4E, leading to mRNA translation.
Expression of gag–Akt in 3T3-L1 or L6 cells results in a much higher phosphorylation of
4E-BP1 even after treatment with wortmannin (84,85). Furthermore, this resultes in an
increase in the rate of protein synthesis in both basal and insulin-treated cells. Akt also
inhibits the activity of PDE-3B and mTOR through phosphorylation at Ser 273 and Ser
2448, respectively, and therefore promotes protein synthesis (60,61).
Insulin receptor substrate-1 (IRS-1) can be inhibited by Akt through
phosphorylation at serines 632 and 662, and the negative regulatory effect Akt was
inhibited by rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), one
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of the downstream targets of Akt. These studies implicate Akt kinase as an additional
negative regulatory pathway for the insulin-signaling cascade (85,86).

Table 2. 2. List of substrates of active Akt

Akt and angiogenesis. Although the contribution of Akt to angiogenesis is still
not clear, several lines of evidence suggest a link between Akt and angiogenesis. Recently
Akt has been shown to phosphorylate the endothelial nitric oxide synthase (eNOS)
leading to a persistent, calcium-independent enzyme activation enhance endothelial NO
synthesis,

which

plays

an

essential

role

of

endothelial

NO

for postnatal

neovascularization (56,57). Most convincingly, eNOS knockout animals are characterized
by an impaired angiogenesis in response to ischemia or VEGF administration (88). The
question remains what is the function of the Akt pathway for endothelial cell migration
and proliferation, which are required for angiogenesis. Several in vitro studies indicate
that endothelial cell migration also depends on NO (89,90). Recent experiments suggest
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that Akt activation is crucial for VEGF-induced endothelial cell migration (91).
Therefore, these studies indeed provide evidence that Akt-dependent NO synthesis
contributes to endothelial cell migration and thereby angiogenesis. Moreover, Stimulation
of cells with a variety of growth factors and cytokines, including epidermal growth factor
(EGF), fibroblast growth factor 2, heregulin, insulin, insulin-like growth factor 1 and 2,
and interleukin-1β induce the expression of HIF-1α protein, HIF-1α DNA-binding
activity, and HIF-1 target gene expression under non-hypoxic conditions. Binding of
these ligands to their cognate receptor tyrosine kinases activates a variety of signal
transduction pathways, including PI3K/AKT/FRAP (FKBP12-rapamycin associated
protein; also known as mammalian target of rapamycin), and the induction of HIF-1α
protein expression can be blocked by wortmannin or LY294002, inhibitors of PI3K, or by
rapamycin, an inhibitor of FRAP. It has also been shown that overexpressed PTEN
negatively regulates the PI3K-AKT-FRAP pathway and dramatically reduces the
induction of HIF1αexpression (92).
Akt and cell cycle progression. The importance of activation of Akt in cell cycle
progression remains to be proven, however several downstream targets of Akt could
potentially regulate cell cycle progression directly. The ability of Akt to induce E2F
activity (80) and its ability to elevate cyclin D1 levels and stablize cyclin D1 protein (93)
may enhance cell cycle progression. It was shown that GSK3β phopshorylates cyclin D1
and redistributes cyclin D1 from nucleus to cytosol and phosphorylation GSK3β of by
Akt can accumulate cyclin D1 in nucleus (93). The induction of c-Myc transcription by
active Akt is also indicated in cell cycle regulation (94).
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The activation of Akt is tightly connected with cell cycle after p21, p27 and
MDM2 have been reported to be the direct substrates of Akt. Zhou et al have identified
the mechanism as phosphorylation by Akt of p21Cip1/WAF1 at T145, which results in
cytoplasmic localization and suppression of growth-inhibiting activity in Her2/neu
overexpression system (95). In addition Akt physically associates with MDM2 and
phosphorylates it at Ser166 and Ser186, which enhances MDM2-mediated ubiquitination
and degradation of p53 and phosphorylation of MDM2 also enhances its nuclear
localization and its interaction with p300, and inhibits its interaction with p19ARF, thus
increasing p53 degradation (96). More recently, it has been reported that p27Kip1 is
phosphorylated by Akt at threonine 157 (T157), which maps within the nuclear
localization signal of p27Kip1, and this phosphorylation causes retention of p27Kip1 in the
cytoplasm, precluding p27-induced G1 arrest (97-103).
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Fig. 7. NLR (nucleotide binding, leucine-rich repeat containing) proteins. NLRPs are defined by three
characteristics: an N-terminal effector domain, a central NBD (nucleotide-binding domain) and C terminal
repeats. When defined, NLR effector domains consist of either a pyrin domain (PYR), caspase recruit
domain (CARD), baculovirus inhibitor of apoptosis repeat (BIR) domains or a transactivation domain
(AD). One NLR protein has an undefined or uncharacterized effector domain (X). APAF1 (apoptoticprotease activating factor 1) also has an N-terminal effector CARD and a central NBD. However, its Cterminal repeats differ from those of the NLRs. NBS-LRR (nucleotide binding site, leucine-rich repeats)
proteins are characterized by a Toll/interleukin-1-receptor (TIR) or coiled-coil (CC) N-terminal effector
domains, a central NBD and C-terminal LRRs.
Figure 7b | Specificity of the NLR proteins involved in the induction of cell death. NLR (nucleotidebinding domain, leucine-rich repeat containing)-mediated cell death appears to be activated by specific
microorganisms (left) or microbial products (right). In response to Shigella flexneri infection of
macrophages, NLRP3 mediates a caspase-1 independent necrotic-like cell death called pyronecrosis.
NLRP3 is also required for Salmonella typhimurium-induced cell death in osteoblasts, and may be involved
in cell death induced by the toxins nigericin and maitotoxin. A caspase-1-dependent form of cell death
called pyroptosis is thought to be mediated by NALP1 in response to anthrax lethal toxin, NAIP5 (neuronal
apoptosis inhibitory protein 5) in response to Legionella pneumophila, and NLRC4 in response to S.
typhimurium. NLRC4 is also involved in S. flexneri at early timepoints and low MOI. BIR, baculovirus
inhibitor of apoptosis repeat; CARD, caspase recruit domain; FIIND, F interacting domain; LRR, leucinerich repeat; NBD, nucleotide-binding domain; PYR, pyrin domain.
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NALP1
NALP1 (also known as DEFCAP/NAC/CARD7) belongs to a newly identified
NALPs (also called PANs or PYPAFs) family of cytoplasmic proteins that have been
implicated in cell responses to apoptotic and inflammatory stimuli (Fig. 7), (104-106).
About 14 members have been cloned in this family and they share very similar domain
structure, characterized by the presence of a Pyrin domain (PYD) at the amino-terminus,
followed by a putative nucleotide binding site (NBS) and a putative regulatory domain
containing multiple leucine-rich repeats (LRRs). Notably, NALP1 is the only family
member with a carboxy-terminal extension containing a caspase recruitment domain
(CARD). The PYD domain is named after the protein pyrin, the product of the familial
Mediterranean fever gene. Each of the four described domain families binds to other
family members through homotypic interactions in order to transduce regulatory signals
to regulate different cellular processes including apoptosis and inflammation.

NBS

domain is responsible for binding ATP. This domain in Apaf-1 is essential for
cytochrome-c-dependent apoptosome formation. The probable function of the LRRs is to
provide a versatile framework for the formation of protein-protein or proteincarbohydrate/lipid interaction (107-110).

Proteins containing both PYD and CARD

domains, such as TMS1/ASC, play important role in regulation of apoptosis and immune
response.

NALP1 was initially reported to induce apoptosis, either through a direct

association with caspase-2 and caspase-9 or indirectly, through an interaction with Apaf1. However, recent studies have demonstrated a crucial role of NALP1 in the activation
of pro-inflammatory caspases. NALP1 plays a critical role in autoimmune disease by
activation of caspase-1 and assembly of inflammasome (111,112).
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The NALP1 inflammasome
The human NALP1 inflammasome was the first caspase-1-activating platform to
be identified. Studies using purified NALP1, ASC and caspase-1 have shown that
NALP1 forms oligomers with caspase-1 in the presence of MDP. Such studies suggest
that caspase-1 is activated by a two-step mechanism whereby microbial MDP induces a
conformational change in NALP1, which in turn allows it to bind nucleotides and to form
oligomers, thus creating a platform for caspase-1 activation (Fig. 8). Because there is no
evidence that MDP binds NALP1, the mechanism that triggers the formation of NALP1
oligomers remains unclear. Notably, ASC is not essential for this process, although its
addition augments NALP1-mediated caspase-1 activation in vitro. Consistent with the
results of the human studies, ASC is not required for the caspase-1 activation mediated
by NALP1b in mouse macrophages, which suggests that ASC acts as an adaptor only for
a subset of inflammasomes. Unlike humans, which have a single NALP1 gene, three
NALP1 paralogs, NALP1a, NALP1b and NALP1c, are present in the mouse genome.
Genetic studies have identified NALP1b as the gene that encodes the molecule
responsible for the pathology induced by lethal toxin, secreted by Bacillus anthracis.
Lethal toxin is a dimeric protein complex consisting of protective antigen, a pore-forming
toxin, and lethal factor, a protease delivered by the protective antigen into the cytosol of
infected cells. Studies have shown that susceptibility to lethal toxin–induced macrophage
death, a critical event in disease pathogenesis, is mediated by NALP1b-dependent
activation of caspase-1. An important function for the NALP1b inflammasome in host
defense is suggested by the observation that mice with the NALP1b ‘susceptibility’ allele
are more susceptible to infection with B. anthracis. The mechanism by which lethal
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factor, a metalloprotease, triggers activation of the NALP1 inflammasome remains to be
determined (113-119).

Figure 8 | Comparison of APAF1 and NLRP3 cell-death pathways. a | Release of cytochrome c from
mitochondria initiates apoptosome-dependent apoptosis. Cytochrome c induces a conformational change in
APAF1 to relieve the intramolecular interactions holding the molecule in an auto-inhibited state. b |
Similarly, NALP1/3 activation or disease-associated NALP1/3 mutations might weaken putative inhibitory
intramolecular interactions between the NLRP3 nucleotide binding domain (NBD) and its C-terminal
leucine rich repeats (LRRs). Using the adaptors ASC (apoptosis-associated speck-like protein containing a
CARD) and CARDINAL/TUCAN, activated NLRP3 aggregates caspase-1 molecules through the
formation of a macromolecular inflammasome complex. Complex formation potentiates subsequent
caspase-1 cleavage and activation. Based on studies of the NALP1 inflammasome, the complex is probably
comprised of 5–7 subunits, each with the ability to recruit pro-caspase-1 molecules. However, formation of
the inflammasome is not the only function of NLRP3. Activated NLRP3 also initiates pyronecrosis, a
molecular pathway of necrotic cell death that is dependent on ASC and proceeds through cathepsin B

NALP1 is mapped to chromosome 17p13.2 approximately 1.5 Mb telomeric to the
p53 tumor suppressor gene. Accumulating studies show frequent loss of heterozygosity
of a chromosome 17p region telomeric to p53 (17p13.1) in human ovarian, breast, brain
and lung tumors, suggesting that a tumor suppressor gene(s) resides within this region
(120-123).
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OBJECTIVES
To understand the molecular mechanism of Aurora-A and Akt pathway in human
oncogenesis and chemoresistance, we will major focus on those two projects.

1). Phosphorylation and activation of androgen receptor by Aurora-A involves in
androgen-independent prostate cancer.
2). Identification of NALP1 as a novel tumor suppressor and a key mediator of Aktregulated autophagy.
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Chapter II
Phosphorylation and activation of androgen receptor by Aurora-A involves in
androgen-independent prostate cancer

Abstract
Aurora-A kinase is frequently overexpressed/activated in various types of human
malignancy including prostate cancer. In this study, we demonstrate elevated levels of
Aurora-A in androgen-refractory LNCaP-RF but not androgen-sensitive LNCaP cells,
which prompted us to examine whether Aurora-A regulates AR and whether elevated
Aurora-A is involved in androgen-independent cell growth.

We show that ectopic

expression of Aurora-A induces AR transactivation activity in the presence and absence
of androgen. Aurora-A interacts with AR and phosphorylates AR at Thr282 and Ser293
in vitro and in vivo. Aurora-A induces AR transactivation activity in a phosphorylationdependent manner.

Ectopic expression Aurora-A in LNCaP cells induces the PSA

expression and cell survival whereas knockdown of Aurora-A sensitizes LNCaP-RF cells
to apoptosis and cell growth arrest. These data indicate that AR is a substrate of AuroraA and that elevated Aurora-A could contribute to androgen-independent cell growth by
phosphorylation and activation of AR.

Introduction
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Androgens, functioning through the androgen receptor (AR), are essential for the
initiation and progression of prostate cancer (1), and androgen ablation therapy usually
achieves significant clinical responses in the beginning. Under the selective pressure of
androgen withdrawal, however, prostate cancers progress to an androgen-independent
stage. As AR is expressed in the majority of androgen-dependent prostate cancer (ADPC)
and androgen-independent prostate cancer (AIPC) (1, 2) and decreasing levels of AR
protein expression reduces both ADPC and AIPC growth in model systems (2, 3), it
appears that the AR signaling pathway plays a critical role in both ADPC and AIPC.
The mechanism for this progression to androgen independence is not completely
understood. Although androgen- independent progression has been correlated with
mutation of the AR gene (4), most androgen-independent prostate cancers express AR
and the androgen-dependent gene PSA, implying that these cells maintain a functional
AR signaling pathway. Furthermore, it has been shown that activation of MAPK, AKT
and tyrosine receptor kinases is involved in the development of androgen escape (5-8).
These pathways act to directly phosphorylate AR, altering AR’s sensitivity to both
androgens and antiandrogens.
Aurora-A, a serine/threonine protein kinase, has been shown to be crucial in
chromosome segregation and centrosome functions (9). Aurora-A has attracted intense
interest after the discovery of its chromosomal localization (20q13.2), a common
amplicon in epithelial cancers (10, 11). It has been shown that 20q13.2 amplifications
involving the Aurora-A gene occur in as many as 12–50% of ovarian, breast, colorectal,
and gastric cancers (12-14). Moreover, up to 57% and 62% of ovarian and breast cancers,
respectively, show overexpression and/or activation of Aurora-A, even where gene
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amplification is not detected (15-19). In addition, ectopic expression of Aurora-A in
murine fibroblasts as well as mammary epithelia induces centrosome amplification,
aneuploidy, and oncogenic phenotype (20, 21).
Previous studies show that Aurora-A is overexpressed in high-grade prostatic
intraepithelial neoplasia and prostate cancer and such expression patterns correlate with
tumorigenicity, clinical staging, surgical margin status, and seminal vesicle invasion (2224).

Aurora-A expression in the radical prostatectomy after neoadjuvant hormonal

therapy specimens correlated significantly with the preoperative value of the serum
prostate specific antigen (PSA), cell proliferative activity and pathological stage (23).
The biochemical recurrence-free survival in patients with a persistent Aurora-A
expression in radical prostatectomy specimens was significantly lower than that in those
with a weak Aurora-A expression (23, 24). After treatment with Aurora kinase inhibitor
VX680, human prostate cancer cell lines (PC3, LNCaP and mouse C1A) exhibited
attenuation of the phosphorylation of histone H3, and reduced survival (25). However,
the mechanism of Aurora-A in prostate carcinogenesis and cancer progression has not
been thoroughly addressed.
In this study, we demonstrated that Aurora-A interacts with AR and
phosphorylates AR-Thr282/Ser293 in the transactivation domain. Aurora-A induces AR
transactivation activity in the presence and absence of androgen in phosphorylationdependent manner. Ectopic expression Aurora-A in LNCaP cells increases the PSA
expression and induces cell survival whereas knockdown of Aurora-A in androgenindependent LNCaP-RF cells sensitizes cells to death.
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Therefore, we provide a direct

evidence that Aurora-A could contribute to prostate carcinogenesis and androgenindependent growth through phosphorylation and activation of AR.
Materials and methods
Reagents and plasmids -Anti-Aurora-A was generated by immunization of
rabbit with GST-Aurora/box-2 fusion protein (16). AR antibody was from upstate. PSA
antibody was purchased from Abcam. Anti-HA and -Flag antibodies were from Sigma.
Recombinant AR and Aurora-A proteins were from Stressgen and Cell Signaling,
respectively. HA-tagged (pHM6) Aurora-A expression plasmids were previously
described (18, 19). Flag-tagged full-length and truncated AR mutants and GST-AR
constructs were created by PCR and sub-cloned into Flag-pCMV2, pcDNA3, and pGEM4T-1 vectors, respectively. Mutation of AR-Thr282/Ser293 to alanine (AR-2A) and
aspartic acid (AR-2D) were prepared with QuikChange site-directed mutagenesis kit
(Stratagene) and were confirmed by sequence analysis. Aurora-A/shRNA and scramble
shRNA were obtained from Sigma.

Androgen response region (ARR3)-tk-Luc was

kindly provided by Robert Matusik (University of Vanderbilt).
Cell, cell culture and transfection - PC3 and DU145 (AR negative, androgen
nonresponsive) cell lines were purchased from American Type Culture Collection.
LAPC-4 cells, which express the wild-type AR and are androgen responsive (26), 22Rv1
(androgen weakly responsive; ref. 27), androgen-dependent LNCaP and androgenindependent LNCaP-RF cell line was kindly provided by W. Jackson Pledger (H. Lee
Moffitt Cancer Center). Cells were cultured in RPMI 1640 medium supplemented with
10% fetal calf serum.

Transfections were performed using Lipofectamine 2000

(Invitrogen).
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In vitro kinase assay, in vivo [32P]Pi cell labeling - In vitro Aurora-A kinase
assay was performed as described previously (16, 17). For in vivo labeling, HEK293
cells were transfected with Flag-AR/HA-Aurora-A. After serum starvation overnight,
cells were labeled with [32P]Pi (0.5 mCi/ml) in phenol red-free MEM without phosphate
for 4 h. Flag-AR was then immunoprecipitated and separated in SDS-PAGE After
transferring to membrane, phospho-AR was detected and quantified.
Western blot, co-immunoprecipitation (co-IP) and RT-PCR - Western blots,
co-IP, were performed as previously described (16, 17).

RT-PCR was performed as

previously described (16, 17) for evaluation of levels of PSA. The primers were:
forward, 5’-GGCAGCATTGAACCAGAGGAG-3’;
reverse, 5’-GGATGAACTTGGTGACCTTCTG-3’.
Luciferase

reporter,

cell

proliferation,

apoptosis

and

chromatin

immunoprecipitation assays - The luciferase reporter assay was carried out as
previously described (17). Briefly, cells were transiently cotransfected with ARR3-Luc,
Aurora-A, wild-type or mutant AR and ß-galactosidase. The amount of DNA in each
transfection was kept constant by the addition of empty pcDNA3 vector. After 36 h of
transfection, luciferase activity was measured using a luciferase assay reagent (Promega).
Transfection efficiency was normalized by cotransfection with ß-galactosidase expression
vector.
For cell growth assay, Aurora-A was ectopically expressed in LNCaP cells and
knocked down in LNCaP-RF cells.

Cells were seeded in the 6-well plate (1x105

cells/plate) cultured in phenol red-free RPMI 1640 medium containing 10% charcoal-
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stripped serum in the absence or the presence of androgen. At days 0, 1, 2, 3 and 4, cells
were trypsinized and accounted. Apoptosis was determined using a Cell Death Detection
ELISAPLUS kit (Roche Applied Science) according to the manufacturer's protocol.
Each experiment was repeated three times in triplicate. The results are expressed as the
enrichment factor relative to the untreated controls. The data represent the mean value of
at least three independent experiments.
Chromatin Immunoprecipitation was performed as we previously described (17, 28).
Briefly, Cells were cross-linked with 1% formaldehyde and then sonicated. The soluble
chromatins were immunoprecipitated with anti-AR or –Flag antibody. The PCR primers
from PSA promoter were as follows: 5’-AGGGATCAGGGAGTCTCACA-3’ and 5’GCTAGCACTTGCTGTTCTGC-3’.
Statistical analysis—Statistical significance was analyzed by unpaired Student's t
test, and p ≤ 0.05 was considered to be statistically significant.

Result
Aurora-A interacts with and phosphorylates AR in vitro and in vivo Previous studies have shown frequent overexpression of Aurora-A in prostate cancer,
which is associated with tumor progression and poor prognosis (22). Moreover, AuroraA expression levels were shown to be correlated significantly with the value of the serum
prostate specific antigen (PSA) and cell proliferative activity (23). Amounting evidence
indicates that AR signaling plays a critical role in the initiation and progression of
prostate cancer (22, 23).
cancer cell lines.

We examined Aurora-A expression in a panel of prostate

Immunoblotting analysis revealed that Aurora-A was elevated in
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LNCaP-RF (e.g., androgen-independent growth) when compared to parental LNCaP cells
(e.g., androgen-dependent), while DU145 and PC3 (e.g., AR-negative/androgenindependent) also express high levels of Aurora-A (Fig. 1A).
us to examine if Aurora-A regulates AR.

These findings prompted

We first performed in vitro kinase assay by

incubation of recombinant AR and Aurora-A. Fig. 1B shows that AR is phosphorylated
by Aurora-A. To determine if Aurora-A phosphorylates AR in vivo, HEK293 cells,
which are AR-negative and express low level of Aurora-A (29, 30), were co-transfected
with Flag-AR and HA-Aurora-A. After 36 h of transfection, cells were labeled with
[32P]orthophosphate for 4 h.

Western blot analysis of Flag-AR immunoprecipitates

revealed that Aurora-A induced phosphorylation level of AR (Fig. 1C).

In addition to

the centrosome, Aurora-A is also distributed to the cytoplasm and the nucleus (22).
Therefore, we also examined whether Aurora-A interacts with AR.
immunoprecipitation was carried in LNCaP-RF cells.

Co-

Endogenous Aurora-A was

readily detected in AR-immunoprecipitates (Fig. 1D) and vice versa (Fig. 1E).

These

findings suggest that AR is a substrate of Aurora-A.
Thr-282 and Ser-293 of AR are phosphorylated by Aurora-A - Sequence
analysis revealed that AR contains three Aurora-A phosphorylation consensus motifs
(R/K-x-S/T-I/V/L/P) at residues Thr282, Ser293 and Thr662 (Fig. 2A). To determine if
Aurora-A phosphorylates these sites, we created GST-fusion proteins which contain
wild-type and Thr/Ser-Ala mutant for each putative phosphorylation site (e.g., GST plus
20 - 30 amino acids of AR with putative phosphorylation Thr or Ser site in the middle).
In vitro kinase assay revealed that wild-type Thr282 and Ser293, but not Thr662 and
Thr282A and Ser293A were phosphorylated by Aurora-A (Fig. 2A). To further confirm
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phosphorylation of Thr282 and Ser293 by Aurora-A, we created Flag-tagged deletion
mutants of AR by truncation of Thr282 or/and Ser293 sites (top panel of Fig. 2B) and
then transfected them to HEK293 cells. Following immunoprecipitation with anti-Fag
antibody,

in

vitro

Aurora-A

kinase

assay

was

performed

using

Flag-AR

immunoprecipitates as substrates. Fig. 2B shows that Aurora-A phosphorylates
fragments N2 (Thr282) and N3 (Thr282 and Ser293) but not fragment N1 in which both
Thr282 and Ser293 are deleted. Moreover, we mutated Thr282 or/and Ser293 to alanine
in full-length Flag-AR.

In vitro Aurora-A kinase assay using Flag-AR

immunoprecipitates as substrates revealed that mutation of either Thr282 or Ser293
decreased the phosphorylation by Aurora-A compared to wild-type AR. However,

45

Figure 1. Aurora-A phosphorylates and interacts with AR. (A) Expression of Aurora-A in prostate
cancer cell lines. Indicated cells were immunoblotted with indicated antibodies. Expression of Aurora-A
was quantified (top panel). Notably, higher level of Aurora-A was detected in androgen-independent
LNCaP-RF than parent LNCaP cells. (B) AR is phosphorylated by Aurora-A in vitro. In vitro kinase was
performed by incubation of recombinant AR with and without recombinant Aurora-A (top panel). Panels 2
and 3 are immunoblots showing the proteins used for in vitro kinase assay. (C) Aurora-A phosphorylates
AR in vivo. HEK293 cells were transfected with Flag-AR together with and without HA-Aurora-A. After
36 h of transfection, cells were labeled with [32P]Pi (0.5 mCi/ml) in phenol red-free MEM without
phosphate and serum for 4 h. Flag-AR was immunoprecipitated, separated on SDS-PAGE and exposed
(top). Expression of the transfected plasmids is shown in panels 2 and 3. Actin was used as a loading
control (bottom). (D and E) Aurora-A interacts with AR. LNCaP-RF cells were immunoprecipitated with
anti-AR and detected with anti-Aurora-A antibody (D) and vice versa (E). NS stands for non-specific band.

Aurora-A could not phosphorylate AR-Thr282/Ser293A (Fig. 2C).

To further

demonstrate Aurora-A phosphorylation of AR at these 2 sites, we performed in vivo
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labeling by transfection of HEK293 cells with Flag-AR and AR-Thr282/Ser293A
together with and without Aurora-A. Fig. 2D shows that Aurora-A phosphorylates wildtype AR but not AR-Thr282/Ser293A. Thus, we concluded that Thr282 and Ser293 are
major AR sites that are phosphorylated by Aurora-A.
Aurora-A induces AR transcriptional activity - Since Aurora-A phosphorylates
AR in vitro and in vivo, we next investigated whether AR transactivation activity is
regulated by Aurora-A. To this end, we introduced AR responsive reporter (ARR3-Luc)
into AR-positive LNCaP and LNCaP-RF and AR-negative PC3 and DU145 lines which
express different levels of Aurora-A (Fig. 1A).

Luciferase assay revealed a higher

promoter activity in LNCaP-RF than LNCaP. Since DU145 and PC-3 are AR negative,
no ARR3-Luc activity was observed even they express high levels of Aurora-A (Fig.
3A), suggesting that AR transactivation activity is regulated by Aurora-A.
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Figure 2. Identify Aurora-A phosphorylation of AR at Thr282 and Ser293. (A) Domain structure and
location of three putative Aurora-A phosphorylation motifs of AR (top). In vitro Aurora-A kinase was
carried out by incubation of recombinant Aurora-A with each GST-fused wild-type and Thr/Ser-Ala
mutated AR motif as substrate (middle). Bottom panel is Western blot showing the GST-fusion proteins
used for the kinase assay. (B and C) Further define the phosphorylation sites with truncated and point
mutated AR. HEK293 cells were transfected with indicated truncation (B) and point mutation (C) of fulllength AR and then immunoprecipitated with anti-Flag antibody. The immunoprecipitates were used as
substrates for in vitro Aurora-A kinase assay (top). Bottom panels are immunoblotting with anti-Flag
antibody showing expression of transfected plasmids. Note: the size of non-specific band (NS) is
comparable with Flag-AR-N3 (B). (D) Aurora-A phosphorylates AR-Thr282/Ser293 in vivo. HEK293
cells were transfected with indicated plasmids and labeled with [32P]Pi (0.5 mCi/ml). Flag-AR was
immunoprecipitated, separated in SDS-PAGE and exposed (top). Panels 2 and 3 show expression of the
transfected AR and Aurora-A.

To further demonstrate importance of Aurora-A in AR transactivation activity,
LNCaP cells were co-transfected with ARR3-Luc and wild-type or dominant-negative
Aurora-A.
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Figure 3. Aurora-A induces AR activity and potentiates androgen action in AR. (A) Basal level of
AR activity is higher in LNCaP-RF than LNCaP cells. Indicated cells were transfected with ARR3-Luc
and -galactosidase. Following 48 h of incubation, luciferase activity was measured and normalized to galactosidase. Results are the mean ± S.E. of three independent experiments performed in triplicate. (B)
Wild-type Aurora-A stimulates and DN-Aurora-A inhibits AR activity. LNCaP cells were transfected with
indicated plasmids and assayed for luciferase activity as described above. (C) Androgen-induced AR
activity is enhanced by wild-type Aurora-A and inhibited by DN-Aurora-A. LNCaP cells were transfected
with ARR3-Luc, -galactosidase and Aurora-A. After 36 of incubation, cells were treated with and
without R1881 and then subjected to luciferase assay. (D) Expression of Aurora-A in AR-negative
HEK293 cells had no effect on ARR3-Luc activity, however, co-expression of AR and Aurora-A
stimulated the reporter activity. HEK293 cells were transfected with indicated plasmids and assayed for
luciferase activity. Asterisks indicate p < 0.05.

After culture for 48 h in phenol red-free medium supplemented with 10% charcoaltreated FBS, we performed luciferase assay and observed that the ARR3-Luc activity was
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induced by wild-type Aurora-A but was suppressed by dominant-negative Aurora-A (Fig.
3B). Moreover, we examined whether Aurora-A potentiates androgen-stimulated AR
activity.

Following transfection with ARR3-Luc and Aurora-A or pcDNA3 vector,

LNCaP cells were treated with and without low concentration of R1881 (0.1 nM and 1
nM) and then assayed for luciferase activity. As expected, AR is stimulated by androgen.
However, ectopic expression of Aurora-A significantly enhances androgen-induced AR
transactivation activity whereas dominant-negative Aurora-A reduces the androgen action
(Fig. 3C).
Subsequently, we investigated if AR is directly regulated by Aurora-A by
transfection of

HEK293 cells with AR, ARR3-Luc and Aurora-A. Luciferase assay

revealed that expression of AR but not Aurora-A alone induces ARR3-Luc activity.
However, the reporter activity is significantly stimulated by co-expression of AR and
Aurora-A in a dose-dependent manner.

Dominant-negative Aurora-A reduces AR-

induced ARR3-Luc activity (Fig. 3D). Collectively, these findings indicate that AuroraA activates AR and potentiate androgen-induced activity.
Aurora-A transactivation of AR depends on Thr282/Ser293 phosphorylation
- Both Thr-282 and Ser-293 are locate within N-terminal transactivation domain with
hormone-independent transcriptional activation function (NTD/AF-1) of AR (Fig. 2A).
Thus, we next examined if Aurora-A transactivation of AR relies on the phosphorylation
of T282/S293. Since AR- negative PC3 cells express high level of Aurora-A (Fig. 1A),
we co-transfected AR, AR-2A or AR-2D with ARR3-Luc into PC3 cells and compared
the luciferase activities. After 48 h of incubation in phenol red-free/10% charcoal-treated
FBS medium, luciferase assay shows that expression of wild-type AR and phosphomimic
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AR-2D induces ARR3-Luc activity whereas AR-2A has much less effect on the reporter
activity. Moreover, transactivation of activity of wild-type AR and AR-2D but not AR2A was enhanced by R1881 treatment (Fig. 4A).
To further demonstrate Aurora-A activation of AR through phosphorylation of
Thr282 and Ser293, HEK293 cells were transfected with ARR3-Luc, different forms of
AR and increasing amount of Aurora-A.

As shown in Fig. 4B, ectopic expression of

Aurora-A induces AR but not AR-2A and AR-2D transactivation activity. The activity
of AR-2D is comparable with that of AR plus Aurora-A.

These data suggest that

phosphorylation of Thr282 and Ser293 not only is required for Aurora-A activation of
AR but also modulates androgen response.
Aurora-A regulates PSA expression, AR DNA-binding activity and
androgen-independent growth - PSA is a major androgen-stimulated gene that is used
to monitor treatment response and progression in patients with prostate cancer. A
previous study has shown that Aurora-A expression correlates with PSA levels and cell
proliferative activity (23). In addition, phosphorylation of AR by protein kinases such as
Src, Akt and MAPK, has been demonstrated to associate with prostate cancer androgenindependent growth (5-7, 27, 28). Thus, we reasoned that Aurora-A phosphorylation of
AR could regulate PSA
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Figure 4. Aurora-A activation of AR depends on phosphorylation of Thr282 and Ser393. (A and B)
Reporter assay. PC3 (A) and HEK293 (B) cells, were transfected with indicated plasmids, treated with and
without R1881. After 46 h of incubation, cells were assayed for luciferase activity. Asterisks indicate p <
0.05.

expression and androgen-independent growth.

To test this, we ectopically expressed

Aurora-A in androgen-dependent LNCaP cells.

After G418 selection, stable Aurora-A

and pHM6 vector-transfected LNCaP cell lines were established (Fig. 5A). Following
treatment with and without R1881, cells were subjected to semi-quantitative RT-PCR and
immunoblotting analyses. Fig. 5B shows that expression of Aurora-A or treatment with
R1881 induces PSA expression.

Combination of Aurora-A expression with R1881

treatment increases PSA expression more significantly than either one alone. Further, we
examined if expression of Aurora-A renders LNCaP cells to androgen-independent
growth. The cells were cultured in phenol red-free RPMI 1640 medium containing 10%
charcoal-stripped serum in the absence or the presence of androgen. Cell proliferation
assay reveals that depletion of androgen inhibits pHM6 vector-transfected cell growth.
Expression of Aurora-A overrides the androgen-depletion effect on cell growth. Notably,
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treatment of Aurora-A-transfected cells with R1881 induces cell proliferation even more
robust than cells treated/transfected with R1881 or Aurora-A alone (Fig. 5C).

In

addition, we compared androgen-depletion-induced apoptosis in Aurora-A- and pHM6tranfected LNCaP cells. As shown in Fig. 5D, the cells expressing Aurora-A largely
abrogates the androgen depletion-induced the programmed cell death.

To further

demonstrate the role of Aurora-A in AR-mediated PSA expression and androgenindependent growth, Aurora-A was knocked down in LNCaP-RF cells. Cells treated with
scramble shRNA were used as controls (Fig. 6A).

The knockdown of Aurora-A

considerably reduces PSA expression, cell growth and cell survival (Fig. 6A-C).
Collectively, these data suggest that Aurora-A regulates androgen-AR-mediated PSA
expression and cell growth.

Figure 5. Ectopic expression of Aurora-A in LNCaP cells induces PSA and androgen-independent
phenotype. (A and B) Effect of Aurora-A and/or androgen on PSA expression. LNCaP cells were stably
transfected with HA-Aurora-A or pHM6 vector and immunoblotted with indicated antibody (A). AuroraA- and pHM6-transfected cells were treated with and without R1881 and subjected to RT-PCR (upper
panels) and immunoblotting (bottom panels) analysis (B). (C and D) overexpression of Aurora-A renders
LNCaP cells to androgen independence. Aurora-A- and pHM6-trasnfected LNCaP cells were cultured in
6-well plates with phenol red-free RPMI 1640 medium containing 10% charcoal-stripped serum in the
absence or the presence of androgen. Cell number was counted in indicated time. Asterisks indicate p <
0.05 (C). The same cells were cultured in either regular FBS or charcoal-stripped serum (CS) for 3 days
and examined for apoptosis using a Cell Death Detection ELISAPLUS kit (D).
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We also investigated if Aurora-A regulates DNA-binding activity of AR.

Chromatin

immunoprecipitation revealed that ectopic expression of Aurora-A in LNCaP cells induces
whereas knockdown of Aurora-A in LNCaP-RF decreases endogenous AR binding to PSA
promoter (Fig. 7A), which indicates Aurora-A regulation of AR DNA-binding activity and
further supports the our findings that Aurora-A regulates PSA expression (Figs. 5 and 6).
We next examined if the AR DNA-binding activity regulated by Aurora-A depends on
phosphorylation of Thr282/Ser293. HEK293 cells were transfected with different forms

of AR together with and without Aurora-A. Fig. 7B shows that DNA-binding activity of
AR-2A is lower than AR whereas phosphomimic AR-2D exhibits higher activity than AR
and AR-2A. Ectopic expression of Aurora-A induces AR but not AR-2A DNA-binding.
Thus, we conclude Aurora-A regulation of AR DNA-binding activity through
phosphorylation of Thr282 and Ser293.
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Figure 6. Knockdown of Aurora-A in LNCaP-RF cells reduces PSA expression and androgenindependent phenotype. (A) Knockdown of Aurora-A decreases PSA expression. LNCaP-RF cells were
transfected with shRNA-Aurora-A and scramble shRNA and detected for expression of Aurora-A (top 2
panels) and PSA (panels 3 and 5) as described in Figure 5. Actin was used as a control. (B and C)
Knockdown of Aurora-A reduces LNCaP-RF androgen-independent phenotype. Aurora-A/shRNA- and
scramble shRNA-treated LNCaP-RF cells were cultured in phenol red-free RPMI 1640 medium containing
10% charcoal-stripped serum and then assayed for cell growth (B) and apoptosis (C).

In addition, we have selected 62 AR-positive prostate cancers, 7 of which were resistance
to anti-androgen therapies, and examined Aurora-A expression. Immunoblotting and
immunohistochemical staining analysis revealed high levels of Aurora-A in 5 resistant
tumors (e.g., 5/7, 71%) as well as in 22 of the rest specimens (e.g., 22/55, 40%; Fig. 7C
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and 7D). These data further support the notion that elevated Aurora-A could contribute
to androgen-independent growth through regulation of AR.

Figure 7. Aurora-A induces AR DNA-binding activity and is frequently upregulated in antiandrogen resistant prostate cancer. (A) Ectopic expression of Aurora-A induces and knockdown of
Aurora-A decreases AR DNA-binding activity. LNCaP and LNCaP-RF cells were transfected with
indicated plasmids and shRNAs. After 48 h of incubation, ChIP assay was performed as described in
“Experimental Procedure”.
(B) Effect of Aurora-A on AR DNA-binding activity depends on
phosphorylation of Thr282 and Ser393. HEK293 cells were transfected with indicated plasmids and then
subjected to ChIP assay. (C and D) Frequent upregulation of Aurora-A in anti-androgen resistant/AR
positive prostate cancer. Seven anti-androgen resistant/AR positive prostate tumors were immunoblotted
with indicated antibodies (C). A representative anti-androgen resistant tumor and prostatic intraepithelial
neoplasia (PIN) were immunostained with anti-Aurora-A antibody (D).

Discussion
Previous studies have demonstrated frequent overexpression of Aurora-A in
prostate cancer (22-25). In particular, elevated levels of Aurora-A are associated with
PSA value, late stage and high grade tumors as well as poor prognosis (22, 23). In this
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report, we demonstrate that Aurora-A phosphorylates and activates AR in vitro and in
vivo. As a result, Aurora-A potentiates androgen-stimulated AR and PSA expression.
Further, we showed that Aurora-A is elevated in androgen-independent LNCaP-RF cells.
Ectopic expression of Aurora-A in androgen-dependent LNCaP cells induces cell
proliferation and cell survival in the absence of androgen. In contrast, knockdown of
Aurora-A in LNCaP-RF cells inhibits cell growth and promotes apoptosis.

These

findings are important for several reasons. First, they provide a direct link between
Aurora-A and the androgen/AR pathway. Second, the mechanism by which elevated
Aurora-A is associated with high levels of PSA and androgen-refractory prostate cancer
has now been uncovered. Finally, they further support the recent findings of Aurora-A
function outside centrosome (29, 30).
The critical role of androgen and AR in prostate cancer development has been
well documented. It has been shown that ligand binding induces AR phosphorylation at
multiple sites, primarily serine/threonine residues at N-terminal transactivation domain,
which include Ser-16, Ser-81, Ser-213 Ser-256 and Ser-308.

Additionally,

phosphorylation of Ser-424, Ser-650 and Ser-791 was also described in response to
androgen (5, 6).

Our study shows Aurora-A phosphorylates AR on Thr282 and Ser293

within the transactivation domain. While they are not androgen-responsive sites, the
phosphorylation of Thr282 and Ser293 potentiates androgen-induced AR activation.
Nonphosphorylatable Thr282/Ser293A mutation reduces androgen-stimulated AR
activity (Fig. 3). These findings suggest that phosphorylation of Thr282 and Ser293 by
elevated Aurora-A enhances androgen-AR action in prostate cancer development and
progression.
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Androgen deprivation is an effective therapy in AR-positive prostate cancer by
inducing apoptosis and cell growth arrest; however, majority of patients eventually loses
its dependence on androgens and progresses to an androgen-independent state. Various
mechanisms have been postulated to account for the conversion of prostate cancer into a
castration-resistant state. One of them is aberrant phosphorylation and activation of AR
by protein kinases, which include serine/threonine kinases Erk1/2 (Ser-514; ref.(27)6),
Akt (Ser-213 and Ser-791; ref. (31-33), CDK1 (Ser-81; ref.(28) and Src family kinases
(Tyr-534; ref. (7)). These phosphorylation events modulate AR activity and result in
androgen-independent growth (27). The AR has an N-terminal transactivation domain
with hormone-independent transcriptional activation function (NTD/AF-1), a central
DNA-binding domain and a C-terminal ligand-binding domain with a hormonedependent transcriptional activation function (AF-2; ref.(34, 35)). Since Thr282 and
Ser293 locate in the NTD region (Fig. 2A), activation of AR by Aurora-A
phosphorylation of these 2 sites was shown to be ligand independent (Fig. 3D).
However, the phosphorylation potentiates androgen-stimulated AR activity (Fig. 4A, 5B
and 5C). In addition, we demonstrated that androgen-independent LNCaP-RF expresses
elevated level of Aurora-A compared to parental LNCaP. Knockdown of Aurora-A in
LNCaP-RF cells decreases PSA expression and AR DNA-binding activity (Figs. 6 and
7). Thus, Aurora-A phosphorylation and activation of AR could contribute to androgenindependent growth and elevated levels of Aurora-A may play a pivotal role in hormone
refractory of the patients with prostate cancer. This notion is further supported by our
finding that the frequency of Aurora-A overexpression in androgen ablation-resistant
tumors is much higher than that in the responsive cases (71% vs., 40%).
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Accumulated studies have shown that Aurora-A plays an important role in
promoting timely mitotic entry by controlling initial centrosomal activation of CyclinB/Cdk-1 (43, 44). Recently, it was shown that Aurora-A promotes the G2-activation of
Polo-like kinase-1 (Plk-1) through direct phosphorylation within the T-loop of Plk1 (45,
46). Active Plk1 controls cyclin-B/Cdk1 activity through the phosphorylation of Cdc25B
phosphatase and the degradation of the Cdk1 inhibitory kinase Wee1 (47, 48). We
previously showed that Aurora-A phosphorylates p53 in centrosome and abrogates p53
DNA-binding activity (17). While Aurora-A is a centrosome kinase, it has been shown
to phosphorylate the molecules outside centrosome, including RalA, TRF1 and HDAC6
(33, 34, 49).

While AR is an important substrate of Aurora-A, Aurora-A function in

prostate cancer development and progression must be the sum of its substrates inside and
outside centrosome. This perception is evidenced by the observation of elevated levels of
Aurora-A in AR-negative and androgen-independent DU145 and PC3 cells (Fig. 1).
Finally, Aurora-A inhibitors are currently in clinical trials (50).

Our findings indicate

that inhibition of Aurora-A or combination with other therapeutic modalities could have
great potential to overcome hormone-refractory prostate cancer.
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Chapter III
Identification of NALP1 as a novel tumor suppressor and a key mediator of Aktregulated autophagy

Abstract
The NACHT leucine-rich repeat protein 1 (NALP1) is a member of the Ced-4
family and locates at chromosome 17p13.2 near TP53 locus. NALP1 has recently been
shown to play a critical role in autoimmune disease by activation of caspase-1 and
assembly of inflammasome. Here we demonstrated frequent somatic mutations and
epigenetic silence of the NALP1 in human non-small cell lung, breast, ovarian and colon
cancer. Restoration of NALP1 resulted in the inhibition of tumorigenic activity of the
cell lines with NALP1 alterations. In addition to apoptosis, the cells expressing NALP1
largely undergo autophagy, which is inhibited by class III PI3K inhibitor 3methyladenine.

Expression of NALP1 induces PI3KC3 kinase activity whereas

knockdown of NALP1 decreases PI3KC3 activation. Further, NALP1 directly interacts
with Beclin 1, a protein required for activation of PI3KC3.

Moreover, Akt

phosphorylates NALP1 and disrupts the interaction between NALP1 and Beclin 1,
leading to abrogation of NALP1-induced PI3KC3 activation and autophagy. Taken
collectively, these data indicate that the NALP1 is a novel tumor suppressor gene on
chromosome 17p13 and plays an important role in tumorigenesis by regulation of Beclin
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1/PI3KC3 autophagic pathway and that Akt inhibits autophagy through regulation of
NALP1/Beclin/ PI3KC3 cascade.

Introduction
NALP1 (also known as DEFCAP/NAC/CARD7) belongs to a newly identified
NALPs (also called PANs or PYPAFs) family of cytoplasmic proteins that have been
implicated in cell responses to apoptotic and inflammatory stimuli (1-3). NALP1 was
initially reported to induce apoptosis, either through a direct association with caspase-2
and caspase-9 or indirectly, through an interaction with Apaf-1 and subsequent
enhancement of apoptosome function (4-6).

More recently, however, studies on

endogenous NALP1 have led to accumulating evidence for a crucial role of NALP1 in
the activation of pro-inflammatory caspases (7,10,11,12). NALP1 activates caspase-1 to
assembly inflammasome (13,14,15).
Autophagy is a highly evolutionarily conserved cellular pathway in which the cell
sequesters cytoplasmic contents in a double-membrane vesicle and delivers them to the
lysosome for degradation (16). This pathway proceeds in a low basal level in most if not
all cells, and it plays a crucial role in nutrient delivery, remodeling, differentiation, and
removal of damaged molecules and organelles. The aberrant regulation of autophagy also
contributes to a number of diseases such as neurodegenerative diseases, microbial
infection, ageing and human cancer (17,18). Although the process of autophagy was
described decades ago, its molecular mechanisms and the signaling pathways leading to
induction of autophagy still remain elusive. Previous studies have shown that the signals
that regulate autophagy are mediated by the target of rapamycin (TOR), the
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phosphatidylinositol 3-kinase (PI3Ks), protein phosphatases, trimeric G proteins and Akt
(19). Notably, class I PI3K inhibits whereas class III PI3K induces autophagy.
NALP1 locates on chromosome 17p13.2 approximately 2.3 Mb telomeric to the
p53 which is on 17p13.1. Frequent loss of heterozygosity of a 17p.13.2 region has been
observed in human ovarian, breast, brain and lung cancers (20-22).

Chromosome

17p13.2 transfer reverts malignant phenotypes in transformed breast epithelial cell (23).
These findings suggest that a tumor suppressor gene(s) resides within this region.
Here we show that NALP1 is frequently inactivated through somatic mutation and
DNA hypermethylation in human cancer from 4 different organs. Ectopic expression of
NALP1 inhibits tumor growth.

Besides apoptosis, NALP1 significantly induces

autophagy by interaction with Beclin-1 leading to activation of class III PI3K. Akt
phosphorylates NALP1 and abrogates its action on class III PI3K as well as proautophagic function.

Materials and methods

Reagents, Cell Lines, Tumor Specimens and Transfection.

Cell culture

reagents were from Invitrogen, Inc. (Gaithersburg, MD); unless otherwise indicated. The
other reagents were obtained from Sigma Chemical Co. (St. Louis, MO). Cell lines were
obtained from American Type Culture Collection (Manassas, VA). Ovarian cancer cells
were maintained in DMEM supplemented with 10% FCS and 0.2 IU/ml porcine insulin.
Other tumor cell lines were cultured as previously described (24,25).

Primary human

tumor specimens were obtained from patients who underwent surgery at H. Lee Moffitt
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Cancer Center, and each sample contained at least 80% tumor cells, as was confirmed by
microscopic examination. The tissues were snap-frozen and stored at -70oC.
Transfection was performed using LipofectAmine Plus (Invitrogen). Stably transfected
clonal cell lines were established after G418 selection.

Expression Plasmid, Cloning of NALP1 Promoter and DNA sequencing.
Myc-tagged full-length NALP1 cDNA was obtained from Dr. John C. Reed (Burnham
Institute, La Jolla, California). Transcriptional start site was determined by 5’-RACE.
Genomic DNA from human K562 cells was used as template to amplify 1.5 kb NALP1
promoter region with GC-RICH PCR System (Roche).

PCR product was cloned into

pGL3 vector (Promega) and the integrity of construct was confirmed by DNA
sequencing. Three CpG islands were identified within this promoter region. Seventeen
exons of NALP1 were PCR amplified and sequenced using Illumina Genome Sequencer
(Sanger Institue).

The mutations were further confirmed with ABI 3130x Genetic

Analyzer at Moffitt Cancer Center Molecular Biology Core.

5-Aza-2'-Deoxycytidine Treatment, Immunoblotting Analysis and Reverse
Transcription (RT)-PCR. Cells were seeded at 2 x 105 cells/T75 flask. The cells were
treated with 5 µM 5-aza-2'-deoxycytidine for 4 days. Protein and total RNA were
isolated for Western blot and RT-PCR analyses.
Bisulfite Sequence, Methylation specific PCR and RT-PCR.Total cellular
DNA was isolated using standard techniques and assayed by bisulfite treatment using the
CpGenome kit (Chemicon), followed by PCR amplification for NALP1 CpG island
located at proximal promoter. The primers for the PCR amplification were, forward:
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AGATGGGTTATATGGTATTTATAGG;reverse:
AATATTTCCCAATAAAAAACTACCC, which generated a 255 bp PCR product. The
PCR reaction consisted of 5 ul of 10 X PCR buffer (1 X buffer contained 16.6 mM
ammonium sulfate; 67 mM Tris, pH 8.8; 6.7 mM MgCl2; 10 mM 2-mercaptoethanol),
dNTPs (each at 1.25 mM), 2 ul of 20 pM primers, and 2.5 ul of DMSO , bisulfitemodified DNA 50-100 ng. The PCR products were separated in 2% agarose gel and
were purified using QIAquick PCR purification kit (QIAGEN) for DNA sequencing.The
second analysis was performed using methylation-specific PCR with primers specific for
either the methylated or modified unmethylated DNA. Primer sequences of NALP1 for
the unmethylated reaction were 5'-AGTATAGGTTTAGATTAGTTGAT -3' (sense) and
5'-AAAAAACTACCCAAACAAACAC-3' (antisense) and for the methylated reaction 5'(sense)

AGTATAGGTTTAGATTAGTTGAC-3'

and

5'-

AAAAAACTACCAAAACAAACAC-3' (antisense).
For RT-PCR, RNA extraction and RT reaction was performed as described
previously.

The

primers

for

the

PCR

amplification

were:

sense,

CTCGGAGTTCTACGTTGGCCAC; antisense AGCTGCTGAGTGGCAGGAGTC. βactin

was

used

as

control,

and

the

primer

used

were

(sense)

CCGCCAGCTCACCATGGATGAT, (antisense) TGACCCATGCCCACCATCAC.
Cell Viability, Apoptosis and Tumorigenicity Analysis. Cell survival and the
programmed cell death were detected with MTT, and Tunel assays as described
previously (24). NALP1 stably transfected cells and control cells were injected into the
right and left flanks (2 x 106 cells/flank) of 6-week-old female nude mice. Tumor
formation and growth were monitored twice a week.
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Autophagy. Autophagy was evaluated by GFP-LC3 aggregation, doublemembrane formation, and LC3 cleavage using fluorescence microscopy, electron
microscopy (EM), and immunoblotting analysis, respectively. For the analysis of GFP–
LC3 punctate foci, cells were transfected with GFP–LC3 for 36 h. After incubation in
EBSS for 3h, the cells were fixed in 3.7% formaldehyde and the number of GFP dots
(≥300 nm diameter) per GFP-positive cell was counted using an automated Zeiss AxioImager Z.1 microscope. In EM experiments, autophagy was evaluated by observing the
typical double-membrane vesicles. A minimum of 100 cells per sample were counted.
All the experiments were repeated three times in triplicate.
In vitro PI3KC3 kinase assay. Cells were transfected with NALP1 and treated
with or without 3-MA for 4h. PI3KC3 was immunoprecipitated with anti-PI3KC3
antibody(ABGENE), washed twice with 1% NP40 in PBS, twice with washing buffer
(100 mM Tris–HCl at pH 7.5, 500 mM LiCl), twice with TNE buffer (10 mM Tris–HCl
at pH 7.5, 100 Mm NaCl and 1 mM EDTA) and pre-incubated for 10 min at room
temperature in 60 µl of reaction buffer (10 mM MnCl2 in TNE) containing 2 µg of
sonicated phosphatidylinositol. The reaction was initiated with addition of 5 µl of ATP
mix (1 µl 10 mM unlabelled ATP, 1 µl γ-32P-ATP and 3 µl H2O) and incubated for 15
min at room temperature. The reaction was terminated by adding 100 µl of 1 M HCl,
extracted with CHCl3:MeOH (1:1), washed twice with MeOH:1 M HCl (1:1), dried with
SpeedVac and resuspended in 20 µl CHCl3:MeOH (1:1).

The products were then

separated on a dried silica, aluminum thin liquid chromatography plate with running
buffer (CHCl3:MeOH:4 M NH4OH; 9:7:2) and visualized using a Typhoon9400
Variable Mode Imager (Amersham Biosciences, Piscataway, NJ).
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Transmission Electron Microscopy.

SW480 cells were transfected with

pcDNA3 or myc-NALP1 for 36h and cultured in EBSS for 3h. The cells were fixed in
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.0) for 1 hr, postfixed in
1% osmium tetroxide in 0.1 M cacodylate buffer for 1 hr, dehydrated with increasing
concentrations of ethanol, and gradually infiltrated with Araldite resin. Ultrathin sections
(70-80 nm) were obtained using an ultramicrotome (RMCMT6000-XL). Sections were
stained with uranyl acetate and lead citrate and examined with a Philips CM10
transmission electron microscope.
Result
NALP1 is mutated in human lung, breast, ovarian and colon cancer. Previous
studies have indicated that additional tumor suppressor gene(s) exists in chromosome 17p
telomeric to p53 (20).

Several candidates have been proposed including OVCA1,

OVCA2, and XIAP-associated factor 1 (XAF1) (21).

Since NALP1 induces apoptosis

by binding to caspase 2 and caspase 9 in addition to activation of caspase 1 to assembly
inflammasome, we reasoned that NALP1 could be tumor suppressor candidate on
chromosome 17p13.2. To this end, total 81 cancer cell lines were examined for NALP1
mutation. Sequence analysis of 17 exons, which cover coding region of the NALP1 gene,
revealed nonsense mutation in 14 (17.3%) cell lines (Figure 1 and Table 1) with more
common in NSCLC (6/30; 20%), breast (2/10, 20%) and ovarian cancer (5/32; 15.6%)
cell lines. Notably, 2 mutations in NSCLC cells resulted in stop codon. Therefore, we
further examined NALP1 mutation in primary NSCLC specimens and found 10 of 61
(16.4%) tumors carrying the nonsense mutations (Table 1). To exclude the possibility of
polymorphosim, the DNAs from 10 corresponding normal lung tissues were sequenced
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and no muation was found. However, the mutations spread whole NALP1 gene with
more mutation in CARD domain (Fig. 1A). These results suggest that NALP1 could be a
tumor suppressor gene.

Fig. 1. NALP1 is frequently mutated in human cancer. A and B, Summary of NALP1 mutations found
in different cancer cell line and primary NSCLC tumor. Small arrows show the location of mutations and
corresponding amino acid changes.

Table 3.1. The list of NALP1 mutations in can cer cell lines and primary NSCLCs.
Cancer

Sample

type

Normal

Tumor

Amino acid

Zygosit

genotype

genotype

change

y

Domain

Lung

Adenocarcinoma

TTG

TGG

L1400W

Hom

CARD

Lung

Melanoma

metastatic

GAA

AAA

E349K

Hom

NBD

necrotic

CGC

TGC

R1366C

Hom

CARD

malignant
Lung

Predominantly
tumoral tissue

Lung

Adenocarcinoma

GAA

TAA

E1458*

Hom

CARD

Lung

Adenocarcinoma

GAA

TAA

E1458*

Hom

CARD

squamous
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Lung

non-small cell, mod-poor

GAA

TAA

E1458*

Hom

CARD

diff.
Lung

Squamous cell carcinoma

GTT

ATT

V136I

Hom

NBD

Lung

Mesothelioma

GAG

CAG

E1308Q

Hom

FIND

Lung

Squamous cell carcinoma

GAG

CAG

E1308Q

Hom

FIND

Lung

Adenocarcinoma

GAA

AAA

E349K

Hom

NBD

Lung

H1437

TGG

AGG

W797R

Hom

LRR

Lung

H1395

AAG

TAG

K660*

Hom

LRR

Lung

H1395

AAA

TAA

K270*

Het

NBD

Lung

H292

ATA

CTA

I440L

Het

NBD

Lung

H322

TCA

ACA

S227T

Het

NBD

Lung

H441

TCA

ACA

S227T

Het

NBD

Breast

MDA157

GCA

ACA

A115T

Hom

NBD

Breast

HCC1143

AGA

AAA

R890K

Hom

LRR

Ovary

RMUGS

CGC

TGC

R1366C

Hom

CARD

Ovary

UTOV3A

CGA

CAA

R308Q

Het

NBD

Ovary

OVCA420

AAG

AAT

K480N

Het

NBD

Ovary

CAOV3

CAG

CGG

Q1013R

Het

LRR

Ovary

A2780/CP70

CAG

CGG

Q1013R

Het

LRR

Colon

HT15

GGG

AGG

G1073R

Het

LRR

Frequent downregulation and hypermethylation of the NALP1 in human
cancer. In addition to mutation, epigenetic silencing is a major mechanism of
inactivation of tumor suppressor gene (26). Since previous reports showed the loss of
17p13.2 in 30-45% of lung, breast, ovarian and colorectal tumors (22), we next examined
expression levels of NALP1 in human cancer cell lines and primary tumors.
Immunoblotting analysis showed that NALP1 protein levels were significant reduced or
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absent in 4 of 9 lung cancer, 8 of 10 ovarian cancer and 5 of 8 colorectal cancer cell lines
(Fig. 2A). Further, downregulation of NALP1 was detected in 16 of 20 colon tumor
tissues and 34 of 40 ovarian tumor cases (Fig. 2B).

Fig. 2. Frequent downregulation of NALP1 in cancer cell lines and primary tumors. Western blot
analysis (WB) of NALP1 expression in indicated cell lines (A) and primary tumor (T) tissues (B). N =
normal tissue

We next considered whether DNA hypermethylation contributes to NALP1
downregulation. Total 14 cancer cell lines with low levels of NALP1 were treated with a
methyltransferase inhibitor 5’-aza-2’-deoxycytidine (AZA) for 4 days and with/without
HDAC inhitibor (TSA) at day 5. Semin-quantitative PCR and immunoblotting analyses
revealed induction of NALP1 mRNA and protein expression in all the cell lines treated
with either 5’-Aza alone or combined with TSA (Fig. 3 and data not shown).
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Fig 3. mRNA and protein levels of NALP1 were induced by 5-Aza. Indicated cell lines were treated
with and without 5-Aza and then subjected to RT-PCR (left panels) and immunoblotting (right panels)
analysis.

The reversal of NALP1 silencing by 5’-Aza suggests that the NALP1 is regulated
through aberrant DNA hypermethylation. Sequence analysis reveals 5 CpG sites within
2.1-kb DNA from NALP1 translation start (ATG) site (referred to as NALP1 putative
promoter). To ascertain if the NALP1 is hypermethylated, we treated DNA from SW480
cell line with bisulfite and sequenced the 2.0 kb of NALP1 DNA. We found 2 CpG sites
were methylated (Fig. 4A). Methylation-specific PCR (MSP) revealed that all cancer cell
lines tested (colon, ovarian and lung cancer cell lines) with low levels of NALP1
expression are hypermethylated with some of them (KM12SM, SW620 and H441)
partially methylated (Fig. 4B). In addition, we also found frenquent hypermethylation of
the NALP1 in primary tumors (Fig. 4C and Table 2).

Collectively, these data indicate

that the NALP1 is frequently downregulated through its promoter methylation in human
lung, ovarian, breast and colorectal cancer.
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Fig 4. NALP1 is hypermethylated in human cancer. A, MSP analysis of colon, lung and ovarian cancer
cell lines. “M” is methylated DNA products amplified with methylation specific primers. “U” is
unmethylated DNA products amplified with unmethylation-specific primers. B, MSP analysis of 4 matched
pairs of colon normal (N) and tumor (T) tissues.

Table 3.2. Methylation status of the NALP1 in cancer cell line and primary tumors.
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Reintroduction of NALP1 inhibits cell proliferation, colony formation and
tumor growth. We next investigated whether restoration of NALP1 would result in
tumor suppression in the colon cancer cell SW480 in which NALP1 is silenced by DNA
hypermethylation. The stably NALP1-expressing clonal cell line was established from
NALP1-transfected SW480 (Fig. 5A).

Tumor-suppressive function of NALP1 was

assessed by cell proliferation and anchonrage-independent growth in soft agar. As shown
in Fig. 5A, cell proliferation is considerably inhibited by expression of NALP1 in
SW480. A similar result was obtained from soft agar culture, in which the colony
formation in soft agar was significantly reduced in SW480-NALP1 cells compared with
SW480-vector (mock) cells (Fig. 5B).
To further explore the in vivo tumor-suppressive ability of NALP1, tumor
formation in nude mouse was tested by subcutaneous injection of SW480-NALP1 and
SW480-mock cells. Within 48 days, tumor was readily visible in left flanks of all 10
mice (injected with SW480-mock cells), but only observed in 2 of 10 mice injected with
SW480-NALP1 cells in right flanks. In addition, the size of tumors in NALP1-expressing
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cells was significantly smaller than that of SW480-mock cells (Fig. 5C). These results
showed that NALP1 has a strong tumor-suppressive ability both in vitro and in vivo.

Fig 5. Restoration of NALP1 inhibits tumorgenic phenotype. A. Growth curve of SW480 cells stably
transfected with Myc-NALP1 and pcDNA3 vector (left). Right panel shows expression of NALP1 in MycNALP1- and vector-transfected SW480 cells . B. Inhibition of colony formation by NALP1 in soft agar.
Indicated cells were grown in soft agar. Columns, mean of three independent experiments. Error bars are
SD; C. NALP1 suppresses tumorigenicity of SW480 cells in nude mice. Upper panel shows a
representative tumor size in a nude mouse. Left flank, SW480-mock; right flank, SW480-NALP1. Bottom
panel is the tumor growth curves of SW480-NALP1 and SW480-mock cells. The average tumor volume of
SW480-NALP1 versus SW480-mock cells was expressed in 10 inoculated mice/cell line.

NALP1 is a pro-autophagic protein. Previous studies have shown that NALP1
moderately induces apoptosis (2). Since tumor suppressor genes, such as Beclin-1 and
p53, extert their tumor suppressor activity through regulation of the second programmed
cell death, autophagy (27-28), we investigated the effect of NALP1 on autophagy.
Transmission electron microscopy (EM) analysis was performed in NALP1-stable
transfected and pcDNA-transfected SW480 cells. Notably, an accumulation of double79

membraned autophagic vesicles was observed in the cytoplasm of the SW480-NALP1
cells compared to the mock cells in both nutrient rich and EBSS (an amino acid and
growth factor-free medium) condition (Fig. 6A). Previous studies have demonstrated that
the visualization of GFP-LC3 punctuation/aggregation is a useful marker of autophagy in
mammalian cells (29). To confirm our EM results, we introduced GFP-LC3 into SW480NALP1 and SW480-mock cells to examine the percentage of punctuated GFP-LC3
staining in GFP-positive cells.

As shown in Fig. 6B, much higher percentage of

punctuated GFP-LC3 staining cell population was detected in SW480-NALP1 than
SW480-mock cells. Another hallmark of autophagy is that cytosolic form of LC3 (LC3I) is conjugated to phosphatidylethanolamine to form LC3-II, which is recruited
autophagosomal membrane and has a faster electrophoretic mobility than LC3-I (30-32).
To further demonstrate the induction of autophagy by NALP1, two forms of LC3 were
analyzed by Wetern blot in SW480-NAPL1 and SW480-mock cells under EBSS
condition.

Fig. 6C shows that expression of NALP1 dramatically increases the

conversion of LC3-I to LC3-II in an EBSS-time dependent manner. Notably, inhibition
of class III PI3K (PI3KC3) by 3-methyadenine (3-MA) or Wortmannin completely
abrogates NALP1-induced autophagy (Fig. 6B).
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Fig. 6. Ectopic expression of NALP1 induces autophay. A, EM analysis of SW480-mock and SW480NALP1 cells. The arrows indicate autophagic vacuoles. B, After transfection with GFP-LC3 for 36h,
SW480-mock and SW480-NALP1 cells were maintained under normal culture condition or starved with
EBSS for 4h in the presence and absence of 3-MA. Cells expressing GFP–LC3 were detected under a
confocal microscopy (upper panel). The cells with GFP-LC3 positive puncta were quantified (bottom
panel). The experiments were repeated three times. C, Immunoblotting analysis of SW480-mock and
SW480-NALP1 with indicated antibodies.

Having demonstrated induction of autophagy by ectopic expression of NALP1,
we next examined the effect of loss-of-function of NALP1 on autophagy. H358 cells,
expressing high level of NALP1 (Fig. 2A), were infected with NALP1-shRNA or
control-shRNA lentivirus and were subsequently trasfected with GFP-LC3. Lentiviral81

mediated expression of NALP-shRNA caused an 80% reduction in NALP1 protein
expression (Fig. 7B). When compared to control shRNA cells, knockdown of NALP1
remarkably decrease in LC3-positive puncta under normal and EBSS culture condition
(Fig. 7A)

as well as induces degradation of p62 protein, a selective substrate of

autophagy (Fig. 7C) (33).

These findings indicate that NALP1 is a pro-autophagic

protein and its action could be mediated by PI3KC3.

Fig. 7. Knockdown of NALP1 inhibits autophagy. A, H358 cells were infected with lentivirus NALP1
shRNA or scramble shRNA and the transfected with GFP-LC3. After culture in normal or EBSS medium
for 4h, Cells with GFP-LC3-positive puncta were detected and quantified. B, In vitro PI3KC3 kinase assay
and C, immunoblotting were performed in NALP1-knockdown or control shRNA treated H358 cells.

NALP1 localizes to autophagosome during the antophagy. To assess the
subcellular localization of NALP1, SW480 cells were transfected with GFP-tagged
NALP1 (Fig. 8A). Approximately 8% of GFP-positive cells displayed a scarce punctuate
staining, and the rest showed a diffuse cytoplasmic staining. The percentage of cells
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containing abundant NALP1 foci was dramatically augmented (~60%) by EBSS.
Immuno-electron microscopy analysis supported the autophagosome localization of
NALP1 (Fig. 8B). These results demonstrate that NALP1 resides predominantly in
autophagosomes during the autophay and could play a pivotal role in autophagosome
formation.

Fig. 8. NALP1 localizes to autophagosome during the autophagy. A, HeLa cells were transfectd with
GFP-NALP1, cultured in normal medium or EBSS and observed under confocal microscopy. B, HeLa
cells were infected with adenovirus-vector based GFP or GFP–NALP1 and then subjected to immuno-EM
analysis using an anti-GFP antibody. The arrows indicate the autophagosome membrane.

NALP1 activation of PI3KC3/Vps34. We next determined the mechanism
whereby NALP1 stimulates autophagy. Since NALP1-induced autophagy is completely
abrogated by PI3KC3 inhibitors 3-MA and wortmannin, we examined if NALP1
regulates PI3KC3.

PI3KC3 is very conserved between yeast (Vps34), Drosophila,

mouse and human. It phosphorylates the 3’-hydroxyl position of the phosphatidylinositol
(PtdIns) ring to produce PtdIns3P (PI3P). Because the PI3P binds to the FYVE finger
domain of the Hrs protein, it could be visualized and quantified by fluorescence of the
GFP-FYVE domain fusion protein, which allows to measure PI3KC3/Vps34 activity
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(31). We transfected HeLa cells with GFP-FYVE together with or without NALP1.
Following incubation of 36 h, the cells were detected under confocal microscope. The
amnount of PI3P was significantly increased in NALP1-treated cells as comapared to
cells transfected with GFP-FYVE alone (Fig. 9A). We also performed in vitro PI3KC3
kinase activity with endogenous PI3KC3 immunoprecipitates prepared from SW480mock and SW480-NALP1 cells using phosphatidylinositol (PtdIns) as substrate. Fig. 9B
shows that PI3KC3 kinase activity is much higher in SW480-NALP1 than in SW480mock. Further, NALP-induced PI3KC3 activity was largely blocked by the PI3KC3
inhibitor, 3-MA (Fig. 9B). In addition, knockdown of NALP1 also substantially reduces
PI3KC3 kinase activity (Fig 8B). These results indicate that NALP1 is an upstream
activator of PI3KC3/Vps34 in HeLa and SW480 cells.

Fig. 9. NALP1 activates PI3KC3. A, HeLa cells were transfected with EGFP-FVYE2 together
with/without NALP1 and visualized under confocal microscope (upper). The autophagic cells were
quantified from ~200 cells expressing EGFP-FVYE2 counted (bottom). B, Immunoprecipitation
was carried out with anti-PI3KC3 antibody in SW480-NALP1 than in SW480-mock cells. The
immunoprecipitates were subjected to in vitro PI3KC3 kinase assay as described in the Methods.

NALP1 interacts with Beclin1 to activate PI3KC3 and induce autophagy. To
define

the

molecular

mechanism

of

NALP1

activation

of

PI3KC3,

coimmunoprecipitation assay was performed to determine whether NALP1 interacts with
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PI3KC3 complex proteins.

Figs. 10 A and 10B shows that NALP1 could co-

immunoprecipitate PI3KC3 complex incuding Beclin1 and PI3KC3. Previous studies
show that Beclin1 directly binds to and activates PI3KC3 (32).

Further, PI3KC3

complex proteins such as UVRAG, ATG14L induce PI3KC3 kinase activity through
direct interaction with beclin1. Thus, we speculated that Beclin-1 function as a bridge
molecule for the NALP1-PI3KC3 interaction. To this end, we knocked down Beclin1 by
shRNA and observed that depletion of Beclin1 largely inhibits NALP1 binding to
PI3KC3 (Fig. 10C).

To confirm the interaction between NALP1 and beclin1, we

performed co-immunoprecipitation using high salt washing buffer to show that NALP1
strongly binds to Beclin1 (Fig. 10D). Moreover, endogenous NALP1 was also found in
Beclin-1 immunoprecipitates and vice versa (Fig. 10E).

Significantly, the interaction

between NALP1 and Beclin1 was further enhanced by autophagic stimulation, i.e.,
EBSS starvation (Fig. 10F).

Furthermore, we assessed if NALP1 colocalizes with

Beclin1. After cotransfection in HeLa cells with pEGFP-NALP1 and pRFP-Beclin1, we
found a remarkable colocalization between NALP1 and Beclin1 during the autophagy.
In addition, knockdown of Beclin1 largely abrogated NALP1-induced PI3KC3
kinase activity (Fig. 11A), LC3 conjugation (Fig. 11B) and GFP-LC3 punctate foci
formation (Fig. 11C).

Based on these findings, we concluded that NALP1 activates

PI3KC3 and induces autophagy through direct binding to Beclin1.
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Fig. 10. NALP1 binds to Beclin1. A and B, Co-immunoprecipitation was performed in HEK293 cells
cotransfected with indicate plasmids. C, Beclin1 was knocked down with shRNA and then co-transfected
with Myc-NALP1 and Flag-PI3KC3. Cell lysates were subjected to immunoprecipitation and
immunoblotting with indicated antibodies. D, Immunoprecipitation was performed in HEK293 cells that
were cotransfected with Myc-NALP1 and Flag-PI3KC3. After overnight immunoprecipitation, the
immunoprecipitates were washed with different concentration of NaCl and then subjected to
immunobloting assay. E, H358 cells were lysed and subjected to immunoprecipitation and immunoblotting
using indicated antibodies. F, HEK293 cells were transfected with Myc-NALP1 and then cultured under
normal or EBSS condition for 3h or 6h. Immunoprecipitation was performed with anti-Beclin1 antibody
and detected with indicated antibodies. G, HeLa cells cotransfected with GFP-NALP1 and RFP-Beclin1
were cultured under normal or EBSS condition for 4h. Colocalization between NALP1 and Beclin1 was
detected under confocal microscopy.
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Fig. 11. Knockdown of Beclin1 blocks NALP1-induced autophagy. HeLa cells were infected with
lentivirus expressing Beclin1 shRNA or scramble shRNA. After selection, in vitro PI3KC3 kinase assay
(A), immunobloting with LC3 antibody (B) and GFP-LC3 puncta assay (C) were performed.

NALP1 interacts with Beclin1 ECD and CCDs. We performed an in-depth
analysis of the interaction between NALP1 and Beclin1. We constructed various deletion
mutants of Beclin1 and NALP1 basis on their domain structures. NALP1 contains an Nterminal PYRIN (PYD) domain, followed by a centrally located NACHT domain, five
tandem LRR domains, a FIND domain, and finally a C-terminal CARD (Fig. 12A) (1).
Beclin1 consists of 3 domains: an N-terminal BH3 domain, a central CCD, and an
evolutionarily conserved domain at the C terminus (Fig. 12B) (34). To identify which
NALP1 domain binds Beclin1, expression vectors encoding individual domains of
NALP1 were cotransfected with a full-length Beclin1 expression plasmid in HEK293
cells. Co-immunoprecipitation assay revealed that the middle region of NALP1

87

containing NACHT domain, LRR domain, the loop between NACHT and LRR, and the
loop between LRR and FIND, co-immunoprecipitated with Beclin1 (Fig. 12A).
Moreover, we fused the central region fragments together (N+L) and also
truncated the central binding domain (∆N+L) of NALP1 to examine their interaction with
Beclin1.

As shown in Fig. 12 B, NACHT-LRR (N+L) but not the NACHT-LRR

deletion form of NALP1 (∆N+L) strongly bound to beclin1. Moreover, GST-pulldown
assay was performed to determine if NALP1 directly interacts with Beclin1 in vitro. Fig.
12C shows that in vitro translated full length and the central binding domain of NALP1
directly binds to GST-beclin1.

Conversely, both the CCD and ECD Beclin1 domains

were required and sufficient for interacting with NALP1 (Fig. 12D). In addition, GFPLC3 puncata assay and immunobloting analysis with anti-p62 and -LC3 antibody show
that the domain of NALP1 that interacts with Beclin1, but not the binding domain
deletion mutants, induces autophay (Figs. 12E and 12F).

88

Fig. 12. NALP1 interacts with Beclin1 through NACHT-LRR domain. A, Co-immunoprecipitation was
performed in HEK293 cells cotransfected with beclin1 and different fragments of NALP1. B, Coimmunoprecipitation was performed in HEK293 cells that were cotransfected with beclin1 and full length
(FL), central binding domain (NACHT-LRR), or binding domain deletion (∆N+L) of NALP1. In vitro
PI3KC3 kinase assay was also performed in HEK293 cells transfected with indicate plasmids. C, GSTpulldown assay was performed with GST-beclin1 and in vitro translated NALP1.
D, Coimmunoprecipitation was performed in HEK293 cells that were cotransfected with NALP1 and different
fragments of Beclin1. E, HeLa-GFP-LC3 cells were transfected with full length, Beclin1-binding domain
(N+L), or the binding domain deletion (∆N+L) of NALP1 and detected under confocal microscopy. F,
HeLa cells were transfected with indicated plasmids and subjected to immunobloting with anti-p62 and LC3 antibodies.
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Fig. 13 NALP1 mutations abolish its apoptosis and autophagy function, A549 cells transfected with
wild type or different mutated forms of NALP1 were treated with VP16 for 36h and then subjected to
Tunel assay (A, B), immunobloting with PARP antibody C), GFP-LC3 puncta assay (D), and PI3KC3
assay(E)

NALP1 somatic mutations abolish its apoptosis and autophagy function. To
evaluate the effect of some of the somatic mutations on NALP1 function, we mutated
those sites on Myc-tag NALP1 and transfected those construct into A549 to check the
apoptosis using TUNEL and PARP cleavage assay (Fig. 13 A, B, C). Compared with
wild type NALP1, most of those mutations impair NALP1 function on sensitizing cell
death under VP16 and CDDP treatment, which implicate NALP1 mutations are involved
in human cancer.
Previous studies show several autophay genes such as beclin1, UVRAG are
mutated in human cancers (35-38). As we identified NALP1 mutations in several human
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cancers, we next investigate if these mutations also affect NALP1 autophagic function.
GFP-LC3 light microscope and PI3KC3 kinase assays were performed in HeLa cells. As
shown in Figs. 13 D and 13E, several NALP1 mutations decrease its autophagic function.
Taken together, these results demonstrate that NALP1 mutation reduces its autophagic
function.
AKT interacts with and phosphorylates NALP1. Although the Akt/mTOR
pathway plays a central role in inhibition of autophagy, mTOR independent pathways
have been recently reported (39-41). It has been thought that Akt could inhibit class III
PI3K to exert its anti-autophagy function, however, there is no such report so far. Since
our data show that NALP1 binds to beclin1 and induces PI3KC3 activity, we
hypothesized that Akt could regulate NALP1 reasulting in inhibition of PI3KC3 and
autophagy. To test this, we first investigated if Akt directly phosphorylates NALP1.
Sequence analysis revealed four Akt phosphorylation conserve sites (R-x-R-x-x-S/T) in
NALP1, two of which locate in the NACHT domain and the others are within LRR
domain (Fig, 14A). To examine whether NALP1 is a direct target of Akt, we performed
co-immunoprecipitation and found that NALP1 interacts with Akt (Fig. 14B).

To

determine whether Akt phosphorylates NALP1, in vivo [32P] labeling was curried out in
HEK293 cells which were co-transfected with NALP1 and constitutively active or
dominant negative Akt.

Fig. 14C shows that constitutively active but not dominant

negative Akt phosphorylates NALP1.
To ascertain the phosphorylation sites of NALP1 induced by Akt, we created 8
GST-fusion (~40Kd) proteins which contain wild-type and serine -> alanine mutant for
each of four Akt putative phosphorylation sites (e.g., S152, S227, S893 and S1017). In
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vitro Akt kinase assay, using individual GST-NALP1 fusion protein as substrate,
revealed that all 4 GST-wild-type NALP1 fusion proteins but not their mutants were
phosphorylated by Akt with more significant phosphorylation at S893 (Fig. 14D).

Fig. 14. Akt interacts with and phosophorylates NALP1. A, Diagram of NALP1 with indicated four
putative Akt phosporylation conseve sites. B, HEK293 cells were co-transfected with Myc-NALP1 and
with HA-Akt, immunoprecipitated with anti-HA antibody and detected with anti-Myc antibody (left) and
vice versa (right). C, In vivo [32P]Pi labeling. HEK293 cells were transfected with indicated expression
constructs, labeled with [32P]Pi (0.5 mCi/ml), and immunoprecipitated with anti-Myc antibody. The MycNALP1 immunoprecipitates were separated in SDS-PAGE, blotted, and exposed to a film (top panel).
Bottom panels show expression of transfected plasmids. D, In vitro kinase assay. Recombinant active Akt
was incubated with indicated GST-fused NALP1 proteins in the presence of [γ-33P]ATP for 30 min. The
reactions were separated in SDS-PAGE and exposed to a film (top). Bottom panel is Ponceau S staining
showing GST-NALP1 proteins ussed. E, In vivo labeling. HEK293 cells were co-transfected full-length
WT or 4A mutant NALP1 together with active Akt and then subjected in vivo labeling assay. F,
Immunoblotting of primary NSCLC tumor tissue lysates with indicated antibodies.

To demonstrate if Akt phosphorylates NALP1 in vivo, [32P] labeling was carried
out in HEK293 cells which were co-transfected with NALP1 and NALP1-4A together
with/without constitutively active Akt and then labeled with [32P]. Fig. 14E shows that
constitutively active Akt phosphorylates wild type NALP1 but not NALP1-4A form.
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We also generated a phospho-NALP1-Ser893 antibody, which exclusively
recognized the wild type but not 4A-mutant NALP1 in the presence of consitutively
active Akt (Fig. 14E). To further show Akt phosphorylation of NALP1 in vivo, we
perfomed immunoblotting with this antibody in Akt-reconstituted Akt-null MEF, wildtype MEF and Akt-null cells. As shown in Fig. 15D shows, phospho-NALP1 level is low
in Akt- knockout cells and increases upon transfection of Akt.

Furthermore, we

examined the phosphorylation status of NALP1 in primary NSCLC tumor tissues and
observed that phospho-NALP1 largely correlates with the phospho-Akt (Fig. 14F).
Collectively, these data indicate that NALP1 is a de novo substrate of Akt.
Akt abrogates NALP1-induced autophagy and PI3KC3 activation. Having
demonstrated Akt phosphorylation of NALP1, we postulate NALP1 phosphorylation by
Akt may affect its autophagic function. To investigate this, GFP-LC3 light microscope
assay was performed in HeLa GFP-LC3 stable cells following transfection of NALP1
together with and without Akt. Fig. 15A shows that overexpression of NALP1 induces
GFP-LC3 puncta formation in both normal and starvation condition. However, Akt1
significantly reduced NALP1-induced GFP-LC3 puncta formation. Similar results were
observed in PI3KC3 in vitro kinase assay (Fig. 15B). These data show that Akt can
inhibit NALP1 autophagic function and PI3KC3 activation.
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Fig. 15 Akt inhibits NALP1 autophagy function. A, Stable HeLa-GFP-LC3 cells were co-transfected
with indicated plasmids and detected under confocal microscopy. Representative results are shown in the
left panel. The percentage of cells with punctate GFP–LC3 fluorescence per total GFP–LC3-positive cells
was quantified from a triplicate of 100 transfected cells (righ panel). The asterisks denote p<0.01. B, HeLa
cells were cotransfected with indicated plasmid and subjected to in vitro PI3KC3 kinase. C, HEK293 cells
were co-transfected with DN-Akt1 or constitutively active Akt together with Myc-NALP1, Flag-Beclin1.
and then immunoprecipitated with anti-Flag and detected with anti-Myc (top) and -Beclin1 (middle)
antibody. D, Akt1-/- MEF cells were infected with adenovirus expressing Akt1. Cell lysates were
immnoprecipitated with anti-beclin1 and detected with anti-Nalp1 (top), -Akt1 (middle), -phospho-NALP1,
or anti-Beclin1 (bottom) antibody.

Consequently, we evaluated the detailed mechanism whereby NALP1 function is
regulated by the phosphorylation by Akt. First, we examined if phosphorylation of
NALP1 by Akt affects NALP1 interaction with Beclin1.

HEK293 cells were co-

transfected with Myc-NALP1, Flag-Beclin 1 and together with dominant negative and
constitutively active Akt or treated with Akt inhibitor API-2/TCN (42). Coimmunoprecipitation revealed that the interaction between NALPl and beclin1 was
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significantly reduced by expression of constitutively active Akt and was enhanced by
dominant negative Akt and API-2 treatment (Fig. 15C), suggesting that Akt
phosphorylation of NALP1 dissociates NALP1 from Beclin 1.

Subsequently, we

examined if this occurs at endogenous protein levels. Briefly, Akt-knockout MEFs were
transfected with and without Akt and then were assessed for NALP1-beclin complex. As
shown in Fig. 15D, knockout of Akt increases NALP1 binding to beclin 1 whereas
restoration of Akt in Akt-null MEF disrupts NALP1-Beclin 1 complex. These findings
confirmed that Akt inhibits NALP1 autophagic function through phosporylation of
NALP1 and disruption of its binding to Beclin 1.
AKT inhibition of autophagy and PI3KC3 depends on the phosphorylation
of NALP1. We also investigated whether NALP1 phosphorylation sites induced by Akt
are required for Akt function in autophagic pathway. We generated a phosphomimic
mutant of NALP1-4D by converting the 4 serine residues to aspartic acid and examined
the binding ability of NALP1-4D, NALP-4A and WT-NALP1 to Beclin1. Following cotransfection of HEK293 cell with NALP1s and Beclin, we performed coimmunoprecipiation and found that NALP1-4D reduces and NALP1-4A increases the
interaction with Beclin as compared to NALP1 (Fig. 16A). In parallel, we compared the
ability of these mutants to activate PI3KC3. In vitro kinase showed that NALP1-4A
increases the PI3KC3 activity whereas NALP1-4D inhibits the PI3KC3 activity (Fig.
16B). Further, we also found that the suppressive effects of Akt on the association of
NALP1 with Beclin1 exclusively depend on the phosphorylation of NALP1, i.e., Akt
inhibits wild-type NALP1 but not NALP1-4A binding to Beclin1 (Fig. 16C).
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Notably, we observed that the basal level of PI3KC3 activity was inhibited by
expression of constitutively active Akt.

Further, constitutively active Akt inhibits

NALP1- but not NALP-4A-activated PI3KC3 (Fig. 16D). To further demonstrate the
role of Akt phosphorylation sites of NALP1 in autophagic function, HeLa cells were
transfected with wild-type, and the mutant NALP1 together with and without Akt.
Immunoblotting analysis shows that ectopic expression NALP1-4A dramatically
promotes the degradation of p62.

Significantly, Akt had no effect on NALP1-4A-

induced p62 degradation (Fig. 16E).

Moreover, GFP-LC3 puncta assay shows that

NALP1-4A increases whereas NALP1-4D inhibits the GFP-LC3 puncta formation
compared with wild-type NALP1 (Fig. 16F).

Expression of Akt inhibits the wild-type

NALP1 induced GFP-LC3 puncta formation but has no effect to the 4A and 4D mutant.
Based these findings, we conclude Akt inhibit autophagy and PI3KC3 through
phosphorylation of the 4 serine residues of NALP1.
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Fig. 16. Akt inhibition of autophagy and PI3KC3 depends on the phosphorylation of NALP1. A,
HEK293 cells were transfected with wild type, 4A or 4D mutatant NALP1. Cell lysates were
immnoprecipitated with anti-Myc and detected with anti-Beclin1 (top) and -Myc (middle) antibodies. B,
HeLa cells were cotransfected with indicated plasmids and subjected to in vitro PI3KC3 kinase. C,
HEK293 cells were co-transfected with DN-Akt or constitutively active Akt together with wild type or 4A
mutant NALP1 and then subjected to immunoprecipitation and immunoblotting with indicated antibodies.
D, HeLa cells were co-transfected with indicated plasmids and then subjected to in vitro PI3KC3 kinase
assay (D) and immunobloting assay with indicated antibodies (E). F, HeLa-GFP-LC3 cells were cotransfected indicated constructs and subjected to GFP-LC3 puncta assay.
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Discussion
Accumulating studies have shown an important role of NALP1 in autoimmune,
autoinflammatory diseases and neurodegenerative disease. In this study, we demonstrated
for the first time that the NALP1 is a tumor suppressor gene. By screening 81 cancer cell
lines and 140 primary tumors, we found that the NALP1 is frequently inactivated through
nonsense point mutation and epigenetic silencing in human NSCLC, ovarian, breast and
colorectal cancer. Further, NALP1 induces autophagy through interaction with Beclin1
leading to activation of PI3KC3. Remarkably, Akt phosphorylates NALP1 and abrogates
NALP1-Beclin1 interaction and PI3KC3 activation during the autophagy, suggesting Akt
regulation of autophagy through not only activation of mTOR but also inhibition of
PI3KC3.
Frequent loss of chromosome 17p13 have been detected in various tumors. A
major tumor suppressor gene identified from this chromosomal region is p53 which
locates at 17p13.1.

Mutation of the p53 is involved in approximately 50% of human

tumors including NSCLC, breast, ovarian and colorectal cancer. Howver, accumulating
studies suggest that another tumor suppressor gene(s) resides in this region due the fact
that some tumors exhibite 17p13 loss but have no p53 alterations (20-22).

Several

candidates have been reported including OVCA1, OVCA2 and XAF1 (23).

We

demonstrated in this study that NAPL1 is either mutated or hypermethylated in ~50%
cancer cell lines and primary tumors examined. NALP1 resides at 17p13.2 and ~2.3-Mb
telomeric to p53. Therefore, NALP1 could be a promising tumor suppressor gene in
17p13.

Based on the Knudson’s two-hit model for tumor suppressor gene, futher
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investigation is required to determine loss of heterozygosity of NALP1 locus in these
tumor specimens.
Although autophagy is thought to perform an essential function in cell survival by
recycling nutrients under starvation conditions, accumulating evidence suggests that
autophagy is also involved in tumor suppressor function by promoting cell death. In
physiological circumstances, baseline levels of autophagy occur in most tissues to ensure
the turnover of long-lived proteins and the elimination of old/damaged organelles. The
autophagic flow is consistently intensified in situations of stress (e.g. nutrient and/or
growth factor deprivation, and hypoxia), favoring the adaptation and survival of cells (4345). Several genetic/epigenetic modifications that are associated with oncogenesis
negatively regulate autophagy, suggesting that basal autophagy may function as a tumor
suppressor mechanism, especially in the first steps of oncogenesis/tumor progression.
NALP1 has been shown to induce moderate apoptosis (46).

In this study, we

demonstrated that NALP1 functions as an important autophagy inducer.

Therefore,

NALP1 could exert its tumor suppressor function through activation of the autophagy
pathway.
Biochemical studies show that two classes of phosphatidylinositol 3-kinases
(PI3Ks) play a critical role in control of autophagy (48-51).
autophagy through activation of Akt/mTOR pathway.

The PI3KC1 inhibits
The acviated mTOR

phosphorylates ULK1/Atg1 and inhibits ULK1:Agt13:FIP200 complex, which has been
shown to involve in initiation of autophagy (43).
positively regulates autophagy.

In contrast, the PI3KC3/hVps34

Recent studies have revealed that PI3KC3/hVps34

mediates autophagy at both the initiation and maturation stage of autophagosomes by
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forming protein complexes with Beclin 1/ATG6 (52-53).

However, the cross-talk

between PI3KC1 and PI3KC3 is currently unknown. Further, mTOR inhibitor-induced
autophagy could be overriden by either Akt or PI3KC3 inhibitor 3-MA. We have shown
that NALP1 activates PI3KC3 by interaction with Beclin 1. Further, Akt phosphorylates
NALP1 and abrogates NALP1-Beclin interaction and PI3KC3 activation. Therefore, this
study provides an evidence of PI3KC1/Akt inhibition of PI3KC3. Akt anti-autophagic
function is mediated by not only activation of mTOR but also inhition of PI3KC3.
It is worth to note that lipopolysaccharide (LPS) induce autophagy through toll
like receptor 4 (TLR4) in primary human macrophages and in the murine macrophage
RAW264.7 cell line (54).

NALP1 has been shown to represent the intracellular

complement to the cell-surface TLR-family receptors involved in innate immunity.
Treatment of macrophages with LPS can increase the caspase-1 activity through the
TLR4 and NALP1 pathway. So it remains to be studied that whether NALP1 also
involved in the LPS induced autophagy pathway.
Recent evidence suggests that autophagy is involved in tumorigenesis and it has
also been shown that the rate of autophagy is reduced during chemical carcinogenesis in
rats. In addition, oncogenes (such as Akt and Bcl-2) suppress autophagy, whereas tumour
suppressors (such as Beclin, DAPK, p53 and PTEN) stimulate autophagy (55-60).
Haploid deletion of Beclin 1 is frequently detected in human breast and ovarian cancers.
In comparison with wild-type mice, Beclin 1+/- mice have a higher frequency of tumour
occurrence, including lymphomas, liver carcinomas and lung cancers(61-63). In
agreement with these findings, expression of NALP1 in SW480 cells supresses cell
proliferation and inhibits tumour growth in nude mice (Fig. 5). Although further studies
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are required to elucidate the precise mechanism of action of NALP1 in Beclin 1-mediated
initiation of autophagy, this study has identified NALP1 as an activator of autophagy and
a tumour suppressor, and provides new evidence in support of the hypothesis that
induction of autophagy could contribute to the prevention and treatment of cancer.
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Chapter IV

Discussion and Conclusion

During cancer development, tumor cells acquire a number of phenotypic changes
that allow them to proliferate both rapidly and unlimitely, invade the surrounding tissue,
survive without their normal microenvironment, and finally, metastasize to other sites (13). These features are usually accompanied with up-regulation of oncogenic and/or downregulation of tumor suppressor signaling. Clearly, as AGC kinases control important
cellular processes it is inevitable that their dysregulation has serious consequences. The
best characterized pathological state in which AGC kinases are involved is cancer. As a
result of intensive worldwide research activity in the last few years, Aurora-A and Akt
signaling pathway has been shown to be involved in tumor development-related cellular
processes, including apoptosis, proliferation, angiogenesis, migration and autophagy (29).
Aurora-A, a serine/threonine protein kinase, has been shown to be crucial in
chromosome segregation and centrosome functions (10). Aurora-A has attracted intense
interest after the discovery that the chromosomal region (20q13.2) in which it is located
commonly undergoes amplification in epithelial cancers associated with poor prognosis
in patients. It has been shown that 20q13.2 amplifications involving the Aurora-A gene
occur in as many as 12–50% of ovarian, breast, colorectal, and gastric cancers (11-13).
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Moreover, up to 57 and 62% of ovarian and breast cancers, respectively, show
overexpression and/or activation of Aurora-A, even where gene amplification is not
detected (14-15).
A previous study shows that Aurora-A is overexpressed in high-grade prostatic
intraepithelial neoplasia lesions and prostate cancer lesions and such expression patterns
correlate with tumorigenicity, clinical staging, surgical margin status, and seminal vesicle
invasion (16). The Aurora-A expression correlated significantly with the value of the
serum prostate specific antigen (PSA), cell proliferative activity and pathological stage
(17). The recurrence-free survival in patients with a persistent Aurora-A expression in
radical prostatectomy specimens was significantly lower than that in those with a weak
Aurora-A expression. After treated with potent Aurora kinase inhibitor VX680 in human
prostate cancer cell lines (PC3, LNCaP and mouse C1A), the phosphorylation of histone
H3 was attenuated, and cancer cell survival was reduced. However, the mechanism of
Aurora-A in prostate carcinogenesis and cancer progression has not been thoroughly
addressed.
In the present study, I demonstrate that Aurora-A interacts with AR and
phosphorylates AR-Thr282/Ser293 within transactivation domain. Aurora-A induces AR
transactivation and DNA-binding activity in the presence and the absence of androgen in
phosphorylation-dependent manner.

Ectopic expression Aurora-A in LNCaP cells

induces PSA and androgen-independent phenotype whereas knockdown of Aurora-A in
LNCaP-RF reduces PSA expression, cell growth and cell survival.

Therefore, we

provide a direct evidence that Aurora-A could contribute to prostate carcinogenesis and
androgen-independent growth through phosphorylation and activation of AR.
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Akt promotes tumorigenesis by phosphorylating substrates involved in apoptosis
(for example, BAD) and the cell cycle (for example, p27KIP), and by phosphorylating
FOXO, which prevents the transcription of genes that promote apoptosis and cell cycle
arrest (for example, BIM and CD95 ligand (also known as FASL)). PI3K/Akt has
emerged as an important mediator to regulate nutrients- and growth factor-induced the
target of rapamycin (mTOR) pathway. The best known biochemical function of mTOR
is to regulate protein translation by initiation of mRNA translation and ribosome
synthesis leading to an increased rate of cell growth (an increase in cell mass and size),
which is required to support the rapid proliferation. Therefore, Akt/mTOR is an important
cascade for tumorigenesis and novel targets for cancer therapeutics. Furthermore, Akt has
an important role in enabling cancer cells to adapt their metabolism to cope with the
demands of enhanced growth and proliferation (17-23).
Autophagy is a highly evolutionarily conserved cellular pathway in which the cell
sequesters cytoplasmic contents in a double-membrane vesicle and delivers them to the
lysosome for degradation (24). This pathway proceeds in a low basal level in most if not
all cells, and it plays a crucial role in nutrient delivery, remodeling, differentiation, and
removal of damaged molecules and organelles. The aberrant regulation of autophagy also
contributes to a number of diseases such as neurodegenerative diseases, human cancers,
microbial infection and ageing.
Cancer is one of the first diseases genetically linked to autophagy malfunction
(25-27). The ATG gene beclin 1 is monoallelically deleted in 40–75% of cases of human
breast, ovarian, and prostate cancer. This is probably mechanistically important in
tumorigenesis, because mice with heterozygous disruption of beclin 1 have decreased

111

autophagy and are more prone to the development of spontaneous tumours including
lymphomas, lung carcinomas, hepatocellular carcinomas, and mammary precancerous
lesions (28). Other components that enhance the autophagic activity of the Beclin 1/class
III phosphatidylinositol 3-kinase (PI3K) complex, including ultraviolet irradiation
resistance-associated gene (UVRAG), Ambra1 and Bif-1 may also play a role in cell
growth control and/or tumour suppression (29-31). In animal models, additional ATG
genes including atg4c also exert tumour suppressor effects, suggesting that tumour
suppression may be a shared property of autophagy proteins that act at different steps of
the pathway. These genetic links between defects in autophagy regulation or execution
and cancer suggest that autophagy is a tumour suppressor pathway.
PI3KC1/Akt/mTOR negatively regulates autophagy.

When nutrients are

abundant, PI3KC1 promotes activation of Akt and mTOR, through receptor tyrosine
kinases; mTOR thereby suppresses autophagosome formation. However, autophagy can
also be induced by mTOR-independent mechanisms: short term treatment of myotubes
with rapamycin induces lysosomal proteolysis to a much lesser extent than what is
observed when Akt1 is inhibited. Leucine starvation has been reported to induce mTORindependent autophagy in cultured myotubes and mTOR has also been found to be
dispensable in other cell systems. Based on previous study, Akt is essential but mTOR is
dispensable in suppressing autophagy (32-34).
NALP1 (also known as DEFCAP/NAC/CARD7) belongs to a newly identified
NALPs (also called PANs or PYPAFs) family of cytoplasmic proteins that have been
implicated in cell responses to apoptotic and inflammatory stimuli (34-36). NALP1 has
also been shown to play a critical role in autoimmune disease by activation of caspase-1
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and assembly of inflammasome (37-42). NALP1 has been mapped to chromosome
17p13.2 approximately 2.3 Mb telomeric to the p53 tumor suppressor gene. Accumulated
studies show frequent loss of heterozygosity of a chromosome 17p region telomeric to
p53 (17p13.1) in human ovarian, breast, brain and lung tumors (43-44), suggesting that a
tumor suppressor gene(s) resides within this region.
Here we demonstrated mutation and epigenetic inactivation of the NALP1 in
several types of human malignancy including carcinoma of lung, ovary, breast and colon,
as well as leukemia. Frequent hypermethylation in CpG islands of the NALP1 promoter
correlates with its transcription silencing in the cancer cell lines and primary tumors.
Restoration of NALP1 resulted in the inhibition of in vitro clonigenicity and tumor
formation in nude mice. In addition to apoptosis, we demonstrated that the cells
expressing NALP1 largely underwent autophagy, which was inhibited by PI3KC3
inhibitor 3-MA.

NALP1 induces PI3KC3 kinase activity and autophagy, whereas

knockdown of NALP1 decreases PI3KC3 activation resulting in the inhibition of
autophagy. We also showed that NALP1 induces autophagy through directly binding to
Beclin 1, a molecule that is required for direct activation of PI3KC3. Moreover, Akt
phosphorylation of NALP1 disrupts the interaction between NALP1 and Beclin 1 leading
inhibition of PI3KC3 activation and autophagy.

Moreover, NALP1 somatic mutations

were frequently found in human cancer, which impair NALP1 pro-apoptotic and proautophagic function. Based on these findings, we conclude that the NALP1 is a novel
tumor suppressor gene on chromosome 17p13 and plays an important role in
tumorigenesis by regulation of Beclin 1/PI3KC3 autophagic pathway and that Akt
inhibits autophagy through regulation of NALP1/Beclin/ PI3KC3 cascade.
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In summary, I have studied the molecular mechanism of two AGC kinase
members such as Aurora-A and Akt involved in human malignant. Aurora-A
phosphorylates AR and induces AR transactivation activity contributing to androgenindependent cell growth in prostate cancer. In addition, I identified the NALP1 as a novel
tumor suppressor gene on chromosome 17p13, which plays an important role in
tumorigenesis by regulation of Beclin 1/PI3KC3 autophagic pathway.

Genetic and

epigenetic inactivation of the NALP1 was found in several types of human malignancy
including carcinoma of colon, lung and ovary, breast as well as leukemia. Moreover, Akt
directly phosphorylates NALP1 leading to inhibition of its pro-autophagic function and
inactivation of its tumor suppressor activity.
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